Novel Treatment: Upgrading the Standard of Care for Neuromyelitis Optica Spectrum Disorder (NMOSD)
This enduring activity will cover the treatment of patients with neuromyelitis optica spectrum disorder.
This enduring activity will cover the treatment of patients with neuromyelitis optica spectrum disorder.
This virtual satellite symposium discusses best practices for managing people with influenza who are at high risk for developing pulmonary complications. 2D animation technology is incorporated throughout the program to highlight the mechanism of action of point-of-care tests (POCTs) and antiviral treatments approved for treatment. Clinical data supporting the efficacy of antivirals and guidance on their use will also be provided.
In this virtual program, we will explore the management of Parkinson’s disease psychosis (PDP)–a condition that affects a substantial percentage of patients with Parkinson’s disease, typically in the later stages. Through this interactive program, clinicians will recognize symptoms, features, and diagnostic best practices in PDP. In addition, participants will learn about the underlying pathophysiology of PDP and treatments targeting these underlying pathways pivotal to the progression of PDP. Through an improved understanding of PDP, clinicians will gain insights and tools to better manage patients with PDP. Through interactive case studies presented by expert faculty, learners will be able to better evaluate pharmacologic approaches to PDP management and the efficacy and safety of approved therapeutic options. In addition, engaging whiteboard animations presented throughout will reinforce concepts learned in didactic portion, ensuring that participants understand the pathophysiology and mechanisms involved in pharmacologic management of PDP.
The case-based online activity will cover the treatment and management of patients with chronic and diabetic kidney disease (DKD).
Upon the completion of this program, attendees should be able to:
This enduring program consists of presentations from expert faculty and simulation challenge animations that will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.
In this virtual program, we will explore the management of Parkinson’s disease psychosis (PDP)–a condition that affects a substantial percentage of patients with Parkinson’s disease, typically in the later stages. Through this interactive program, clinicians will recognize symptoms, features, and diagnostic best practices in PDP. In addition, participants will learn about the underlying pathophysiology of PDP and treatments targeting these underlying pathways pivotal to the progression of PDP. Through an improved understanding of PDP, clinicians will gain insights and tools to better manage patients with PDP. Through interactive case studies presented by expert faculty, learners will be able to better evaluate pharmacologic approaches to PDP management and the efficacy and safety of approved therapeutic options. In addition, engaging whiteboard animations presented throughout will reinforce concepts learned in didactic portion, ensuring that participants understand the pathophysiology and mechanisms involved in pharmacologic management of PDP.
Recent advances in treatment strategies promise to improve the lives of patients with sickle cell disease or hemophilia. In this program, experts in both fields will assist clinicians in developing individualized management plans using state-of-the-art and emerging therapies, and highlight opportunities to implement multidisciplinary, patient-centered approaches to care. Case studies and interactive question and answers will provide learners practice in applying patient-specific factors to treatment decisions. This activity will feature whiteboard animations that will reinforce learning and help participants gain a higher level of understanding.
This case-based online activity will help gynecologists and medical oncologists improve the timeliness of screening for women at risk for cervical cancer and the accuracy of diagnosis; and recognize the limitations of currently available regimens for recurrent and metastatic disease. The education will also seek to expand awareness of the integral role that the immune system plays in the pathology of cervical cancer and how IO agents in late-stage development for patients with recurrent or metastatic cervical cancer potentially could be integrated into practice once available.
This activity is designed to meet the educational needs of rheumatologists, rheumatology-related nurse practitioners, physician assistants and fellows.
This activity will explore strategies to improve glycemic and metabolic outcomes in patients with type 2 diabetes mellitus (T2DM). A review of clinical trial data will enable clinicians to personalize the selection of therapies for patients and examine the role of emerging dual GIP and GLP-1 receptor agonists in the management of type 2 diabetes and obesity.
This program is intended to help HCPs improve the diagnosis of SMA among older adolescent and adult patients and learn how the changing treatment landscape may alter patient outcomes.
This enduring activity is intended for dermatologists, pediatric dermatologists, and dermatology advanced providers (NPs and PAs) who are involved in the care and treatment of patients with alopecia areata.
This series of TeleECHO activities will discuss the management of patients with advanced and/or metastatic (m) renal cell carcinoma (RCC) and therapeutic options available in the first line setting.
This case-based online activity is designed to provide clinicians with an overview of prurigo nodularis (PN), the importance of early diagnosis, and our latest understanding of the management options for the disease.
This activity is designed to help lipidologists, cardiologists, and other healthcare professionals involved in the management of US veterans with familial hypercholesterolemia (FH) to improve cholesterol and cardiovascular outcomes for veteran patients.
This activity will help participants to overcome clinical inertia and other potential barriers to timely and appropriate insulin therapy in patients with type 2 diabetes. Participants will be equipped with an enhanced ability to select, titrate and adjust basal insulin regimens, and to successfully educate and empower their patients to self-manage their diabetes.
This enduring activity is a faculty-led didactic and case-based lecture focusing on the management of patients with hepatocellular carcinoma (HCC).
This activity provides a practice-based learning experience for dermatologist and primary care physicians regarding the assessment and treatment of alopecia areata (AA). By participating in this Simulation Center, learners will observe an interaction between a physician and their patient with AA and will test their knowledge of diagnosis and management at key decision points along the way. The burden of AA and its associated comorbidities will be highlighted, and you will learn strategies to effectively address the psychosocial impacts of this disease with your patients.
This enduring activity focuses on the treatment and management of patients with generalized myasthenia gravis (gMG).
This enduring activity discusses the underlying autoimmune causes of alopecia areata (AA) and the rationale of targeted treatment approaches. The burden of AA and its associated comorbidities will also be presented, and you will hear strategies to effectively address the psychosocial impacts of this disease with your patients. Features of this program include whiteboard animations and case studies.
This enduring activity is designed to review early identification strategies for MS; assess the variety of treatments available to treat the condition; and discuss ways to improve adherence, engagement, and clinician/patient communication.
This CME activity will help participants identify the characteristics of older adults with type 2 diabetes that require special consideration, assess older patients with type 2 diabetes, and develop personalized pharmacotherapeutic strategies for older patients with type 2 diabetes, both in the community and in long-term care, that include the use of fixed-ratio GLP-1 receptor agonist/insulin combinations. The activity features a Situation Room, a unique online program which employs a patient simulation platform. The situation room provides interactive quizzing, testing, and training via immersion-focused 3D simulations of scenarios encountered by clinicians who care for older adults with type 2 diabetes. The experience will be customized based on who is using the simulation. One track will be aimed at geriatricians and endocrinologists, and the other will be aimed at PCPs, physician extenders and consultant pharmacists. A slide presentation will guide the learners in their selection of treatment strategies.
This enduring activity will discuss the causes of alopecia areata and how to best manage this disease. Expert faculty will highlight the burden of alopecia areata and will offer participants strategies for implementing treatment plans that will not only address the disease itself, but also the overall health challenges for this patient population.
This case-based enduring activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.
This enduring activity discusses the underlying autoimmune causes of alopecia areata (AA) and the rationale of targeted treatment approaches. The burden of AA and its associated comorbidities will also be presented, and you will hear strategies to effectively address the psychosocial impacts of this disease with your patients. Features of this program include whiteboard animations, case presentations, and a pre-recorded Q&A session.
This enduring program is designed for allergists, otolaryngologists, primary care clinicians, and other clinical team members who manage chronic rhinosinusitis with nasal polyps. In this program, we will aim to discuss the burden and pathophysiology of CRSwNP, review guidelines for diagnosis and short- and long-term management, look at clinical data and biomarkers on current and novel anti-inflammatory biologics, and teach clinicians how to apply best practices for the interdisciplinary development of individualized treatment plans for these patients. We will use a combination of didactic lecture, video animations, and patient cases to effectively teach clinicians who manage this condition.
This enduring virtual activity targets healthcare gaps related to the diagnosis, treatment, and individualized management of AD, impacting outcomes through identifying burdens affecting quality of life, assessing disease severity when considering topical vs systemic intervention, and utilizing strategies in shared decision-making when determining guideline-based care.
The online activity will address renoprotective therapies in care of patients with T2D and CKD with a focus on mineralocorticoid receptor antagonists and SGLT2 inhibitors. Discussion will include mechanisms of action, emerging clinical data, best practices in screening patients, and management considerations for hyperkalemia.
This enduring TeleECHO activity will explore the use of JAK inhibitors for the management of rheumatoid arthritis (RA) through interactive case studies. Faculty will review emerging efficacy and safety data, discuss guideline recommended care of RA, and help clinicians identify candidates for treatment with JAK inhibitors.
This enduring activity targets healthcare gaps related to the diagnosis, treatment, and individualized management of hepatorenal syndrome with acute kidney injury (HRS-AKI), impacting outcomes through diagnosis and differentiation from other forms of AKI as well as individualizing pharmacotherapeutic management.
This educational activity will explore the use of monoclonal antibodies for the treatment and prevention of COVID-19 in pediatric patients. A review of available clinical data will help clinicians identify candidates for therapy and select appropriate treatments based on the most up-to-date information.
This enduring virtual activity targets healthcare gaps related to the treatment and management of AD in urban communities, impacting outcomes through identifying determinants that impact health in urban communities, implementing strategies in disease severity assessment across varying skin tones, and guideline-based care.
In this comprehensive and interactive CME activity, we will be presenting important topics in the area of diabetic kidney disease. The program includes slide-based material interspersed with interactive questions and case studies to enhance learning. The focus is on kidney disease in the diabetic patient, specifically mechanisms of disease, diagnosis and evaluation, and therapeutic options.
In this program; we will aim to discuss the cost burden and pathophysiology of CRSwNP, review guidelines for diagnosis and short- and long-term management, look at clinical data and biomarkers on current and novel anti-inflammatory biologics, and teach pharmacists how to apply best practices within the framework of interdisciplinary managed care of these patients. We will use a combination of didactic lecture, video animations, and patient cases to effectively teach pharmacists who see this condition.
This enduring MedGames is an interactive gamification-style CME activity that covers important topics in chronic spontaneous urticaria (CSU). The educational format of this program is engaging and covers the economic and physiological burden of CSU, diagnostic algorithms, guideline recommended step-care management, and efficacy and safety of current and emerging biologic therapy.
This enduring TeleECHO educational series targets healthcare gaps related to the familiarity and understanding of CDK4/6 inhibitor clinical trial designs and results on efficacy, safety, and real-world studies, impacting outcomes through current practice patterns and treatment strategies in the management of HR+/HER2- metastatic breast cancer (mBC).
This enduring activity focuses on the treatment and management of cold agglutinin disease.
This case-based online enduring activity will cover the treatment and management of patients with Type 2 diabetes mellitus (T2D) who are at high risk for chronic kidney disease.
Oncology nurses are in an inherently valuable position to be in the frontline of breast cancer treatment for patients. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience.
This educational activity will assess the pathophysiology and disease domains of psoriatic arthritis as well as review FDA-approved agents and their roles in in treating the disease. Additionally, we will discuss the appropriateness of combination or monotherapy regimens and unanswered questions in this area.
This online activity will cover the pneumococcal vaccinations in specific populations.
This live virtual activity will help clinicians reduce the significant delay between onset of symptoms and diagnosis of axial spondyloarthritis (axSpA) by identifying patients with inflammatory back pain who should be promptly referred to a rheumatologist for further assessment. Case studies and engaging whiteboard animations on the features of axSpA and the consequences of delays in diagnosis create a memorable and practical learning experience.
This enduring activity will help clinicians reduce the significant delay between onset of symptoms and diagnosis of axial spondyloarthritis (axSpA) by identifying patients with inflammatory back pain who should be promptly referred to a rheumatologist for further assessment. Case studies and engaging whiteboard animations on the features of axSpA and the consequences of delays in diagnosis create a memorable and practical learning experience.
This activity provides a practice-based learning experience for medical oncologists, pulmonologists, nurse practitioners, and other health care providers, regarding the assessment and treatment of non-small cell lung cancer (NSCLC) in the first-line setting. By participating in this Simulation Center, learners will observe an interaction between a patient with NSCLC and their healthcare provider, and will test their knowledge of diagnosis and management at key decision points along the way.
Pneumococcal disease caused by Streptococcus pneumoniae is the leading cause of pneumonia-related deaths and poses an important global public health concern. There are several vaccines available for prevention of this disease, but their implementation in the clinic is challenged by complex recommendations of their administration for various patient populations and by complicated guidelines for appropriate spacing and sequencing of vaccine schedules. Managed Care Specialists need to understand the nuances of pneumococcal vaccines to guide physicians on their appropriate use to reduce infections and improve clinical outcomes, particularly for at-risk patients. This educational activity will explore the impact of pneumococcal disease, pathophysiology of disease, guidelines recommendations, and strategies for managing vaccine hesitancy. In addition to a didactic presentation, the program features animations and case discussions to highlight the different aspects of this disease.
Through a series of informative lectures and podcast interviews, this educational series will target clinicians in the field of rheumatology who have patients with psoriatic arthritis. We will provide the latest information on clinical presentation, differential diagnosis, therapeutic targets, and clinical trial data on current and emerging therapies to help learners reduce both short- and long-term consequences of the disease.
This online activity with an integrated case-based learning component will enable clinicians to recognize emerging targets in the management of anemia of chronic kidney disease (CKD) through an understanding of the underlying pathophysiology and clinical trials evaluating novel therapies. By integrating these data with the current standards of care in the management of anemia of CKD, clinicians will be better able to understand the role of multiple healthcare professionals in the management of this common complication of CKD. Additionally, the integrated case-based activity within this program will ensure that healthcare professionals can readily translate learnings to patient interactions, ensuring that patients and the healthcare team are aware fully aware of emerging therapeutic alternatives.
This enduring activity will focus on the T-cell Immunoreceptor with Ig and ITIM Domains (TIGIT).
This enduring TeleECHO program will explore the role of real-world evidence in informing management decisions of elderly and frail patients with relapsed and refractory multiple myeloma (RRMM). A brief didactic presentation will discuss prognostic features and key management considerations for the elderly and frail patient populations. A summary of clinical trial data and real world evidence to inform treatment selection in the first-line and relapse settings will also be presented. Interactive case studies will illustrate strategies for patient counseling and treatment selection in elderly and frail patients with RRMM.
This activity invites learners to experience a virtual world illustrating personalized therapy for advanced non-small cell lung cancer (NSCLC). It provides a unique opportunity for learning about checkpoint inhibitor mechanisms in NSCLC, important biomarkers used to guide clinical decisions, and immune-related adverse events.
This enduring activity covers the pathogenesis of Metastatic Castration-resistant Prostate Cancer (mCRPC) and which patients may benefit from using PARP Inhibitor–based Combinations.
This interactive online activity will explore the diagnosis and management of hypertrophic cardiomyopathy (HCM). A didactic presentation by expert faculty will review guideline recommendations and risk factors for complications, discuss pharmacologic and surgical treatment options, and examine clinical trial data on emerging agents. An animated case will allow learners to apply what they have learned in a simulated clinical encounter.
This CME program has been designed for endocrinologists who treat patients with type 2 diabetes. It aims to help learners evaluate the impact of weight loss and timely treatment intensification in patients with T2DM on glycemic and metabolic outcomes, and to increase knowledge of the mechanism of emerging GIP/GLP-1 receptor agonists and their impact on glycemic outcomes and body weight in order to advantageously integrate them into clinical practice when available.
This CME program has been designed to provide participants with the knowledge necessary to simultaneously address weight management and glycemic control in patients with type 2 diabetes and obesity/overweight. Participants will gain a greater understanding of guidelines-recommended pharmaceutical and lifestyle management strategies, and learn how incretin therapies with beneficial impacts on glycemic outcomes and body weight can be integrated into clinical practice. In addition to viewing a faculty presentation of relevant clinical data and guidelines, learners will participate in Med Games, an engaging gamified learning activity featuring interactive quizzes and video case studies that provide the opportunity to make decisions about patient care and get immediate feedback.
This enduring activity has been designed for HCPs treating metastatic castration-resistant prostate cancer (mCRPC) to improve: knowledge of the mechanisms of action of PARP inhibitor–based combinations for the treatment of patients with mCRPC with or without DNA damage response (DDR) alterations; awareness of new clinical data on the efficacy, safety, and tolerability of emerging PARP inhibitor–based combinations with different mechanisms of action for the treatment of patients with mCRPC; and their ability to develop individualized management plans for patients with mCRPC with or without DDR alterations that include PARP inhibitor–based combinations if appropriate.
This enduring MedGames is an interactive gamification-style CME activity that covers important topics in chronic spontaneous urticaria (CSU). The educational format of this program is engaging and covers the economic and physiological burden of CSU, diagnostic algorithms, guideline-recommended step-care management, and efficacy and safety of current and emerging biologic therapy.
In this educational activity, expert faculty will discuss the use of approved and authorized treatments for the management of patients hospitalized with COVID-19. A review of clinical trial data on the efficacy and safety of therapeutic options and strategies for selecting therapy based on disease severity and clinical factors will allow clinicians to reduce the need for invasive ventilation and improve patient outcomes.
This enduring activity will explore the diagnosis and management of NTM-LD. Whiteboard animations will identify common pitfalls that lead to delays in diagnosis and look at the mechanism of action of novel therapies for refractory disease. A case-based didactic lecture led by expert faculty will review guideline-recommended care, strategies to minimize adverse events, and clinical trial data on newer treatment options.
This case-based enduring activity will focus on the epidemiology, pathophysiology, diagnosis, and treatment of eosinophilic esophagitis (EoE). Patients with EoE are often diagnosed after symptom onset, leading to greater chronic inflammation, and treatment plans are frequently not tailored to individual needs. This activity is intended to help healthcare professionals diagnose EoE earlier and provide individualized treatment based on guidelines, recent clinical data and patient characteristics.
This educational activity will review clinical trial data on the use of authorized therapies for the management of patients hospitalized with COVID-19 and explore strategies to incorporate these therapeutic options into clinical practice. This program includes a whiteboard animation on the role of inflammation in the pathophysiology of severe COVID-19 and the mechanism of action of available treatment options.
This enduring activity will cover the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD).
This enduring activity is designed to review the importance of chronic kidney disease (CKD) risk reduction in patients with T2D, how to evaluate opportunities to screen for CKD risk in patients with T2D and target reductions in albuminuria, the manageability of hyperkalemia and uniqueness of novel therapy, and key takeaways and practice changes.
This enduring activity will focus on the latest updates in the optimal management of cancer-associated venous thromboembolism (VTE) based on risk stratification, clinical trial data, and appropriate guideline-informed strategies to optimize clinical outcomes. This program will inform participants of the latest best practices as recommended by professional guidelines and will equip participants to integrate multidisciplinary care and shared decision-making in practice.
This case-based enduring activity is designed to provide clinicians with an overview of Short Bowel Syndrome and highlight its impact on patient quality of life.
This educational activity will explore best practices for the management of rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Expert faculty will review the latest information on clinical presentation, treatment recommendations, and clinical trial data on available therapies to help learners reduce both short- and long-term consequences of disease. An innovative simulation center will allow clinicians to apply what they have learned in an interactive, animated case.
Oncology nurses are in an inherently valuable position to be in the frontline for treatment of HER2-positive solid tumors. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. For additional resources, please visit www.oncologynurse-ce.com.
This online activity is designed to increase HCPs recognition of metabolic pathways involved in the pathophysiology of Gaucher disease; confidence discussing clinical trial data supporting improved outcomes in Gaucher disease; understanding of the potential for treatment to modify outcomes in Gaucher disease; and understanding of shared decision-making best practices for long-term management of Gaucher disease.
This enduring activity has been designed to help dermatologists, pediatric dermatologists, primary care physicians, advanced practice providers (NPs and PAs) and other healthcare providers who are involved in the care and treatment of patients with atopic dermatitis to assess patients for physical and psychosocial burdens of AD; identify candidates for systemic therapies; better evaluate recent clinical trial data on the efficacy and safety of JAK inhibitors for the management of moderate-to-severe AD; and apply evidence-based approaches to manage moderate-to-severe AD and monitor for adverse events.
This podcast will explore the management of patients with metastatic colorectal cancer (mCRC). Faculty will review strategies on personalizing the selection of treatment options based on molecular testing; and discuss the management of adverse events with targeted treatments for BRAF V600-mutant mCRC.
This enduring series will discuss the recognition and management of CKD risk in patients with T2D.
This activity discusses the growing impact of dengue fever worldwide and strategies to mitigate its spread. Featured topics of this program include signs and symptoms of dengue fever and differential diagnoses, the lifecycle of a dengue infection, and clinical trial data of approved and emerging vaccines.
This Community Whiteboard ECHO Series and Online Enduring activity is designed to increase the multi-disciplinary oncology care team recognition of the role of targeted and bispecific antibodies in management of relapsed/refractory DLBCL; strengthen their understanding of clinical trial outcomes and adverse events with targeted and bispecific antibodies; and improve their awareness of multidisciplinary best practices for managing adverse events from targeted therapies.
This activity features education regarding hormone therapy for children and adolescents with growth hormone (GH) deficiency. The program will discuss the diagnosis of GH deficiency, challenges of currently available therapies, clinical data of emerging therapies, and strategies to personalize care for childhood growth hormone deficiency (CGHD).
This case-based online activity is designed for retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with neovascular age-related macular degeneration and/or diabetic macular edema. The activity aims to improve treatment for patients who do not achieve optimal outcomes due to insufficient responses to therapy or insufficient adherence. In addition, it will elucidate the benefits and limitations of current therapeutic approaches, equip participants with strategies for improving the durability of treatment response in patients receiving intravitreal therapies, and provide education on new and emerging treatment strategies.
PODCAST ACTIVITY: These podcasts provide an up-to-date perspective on improving treatment for patients with neovascular age-related macular degeneration and/or diabetic macular edema who do not achieve optimal outcomes due to insufficient responses to therapy or insufficient adherence. This series of podcasts will elucidate the benefits and limitations of current therapeutic approaches for patients with nAMD or DME, equip participants with strategies for improving the durability of treatment response in patients receiving intravitreal therapies, and provide education on new and emerging treatment strategies.
This activity will explore emerging treatment options and novel management strategies of patients with relapsed/refractory MCL or CLL/SLL.
This simulated activity depicts conversations between an oncologist, a pathologist, and a patient diagnosed with non-small cell lung cancer (NSCLC). You will watch as they engage with each other throughout the various stages of a patient’s journey, from the initial pathologic and oncologic workup at initial presentation to disease recurrence. You will participate in the simulation by answering questions throughout the activity. A brief slide presentations is available within each simulation center activity to enhance your understanding of immunological biomarkers.
This enduring TeleECHO program will explore key clinical practice insights for management of patients with BRAF-mutated metastatic melanoma. Over the course of this activity there will be discussion of the clinical profiles of frontline combination immuno- and targeted treatment options in BRAF-mutated metastatic melanoma as well as emerging data from clinical trials and real-world studies examining sequencing of these therapies. Interactive case studies will illustrate strategies for treatment selection, mitigation of adverse events, and management considerations for patients with BRAF-mutated metastatic melanoma.
This case-based virtual activity will cover the pathophysiology, clinical course, and underlying causes of NCFBE; summarize current evidence-based strategies for the diagnosis and treatment of patients with NCFBE; describe how neutrophilic inflammation and high levels of neutrophil serine proteases in patients with NCFBE provide the rationale for targeted treatment; and evaluate clinical data on therapies for NCFBE targeting neutrophilic inflammation neutrophil serine proteases.
This enduring activity discusses emerging treatments for advanced non-small cell lung cancer (NSCLC). It includes animations for learning about the role of TROP2, HER2, and HER3 in the pathogenesis of NSCLC, including the mechanisms of action and design of antibody drug conjugates targeting these pathways.
This enduring activity has been designed to help obstetrician gynecologists and other HCPs involved in the care and treatment of patients with uterine fibroids (UF) and/or endometriosis to better support prompt initiation of treatment through early and accurate diagnosis. Key goals of this activity are to justify the need for new treatment options for patients with UFs and endometriosis based on the challenges associated with standard-of-care medical therapies and assess the results of clinical trials supporting the efficacy and safety profiles of newly approved and emerging combination therapies including GnRH antagonists for the long-term management of UFs and endometriosis. Finally, this program will outline individualized management plans for patients with UFs based on new clinical guidance & shared decision-making.
The majority of Veterans with migraine are seen in the primary care setting. Therefore, primary care professionals (PCPs) managing Veterans with migraine will need education on the most effective ways to treat it using currently available therapeutic options. This educational program seeks to effectively close those gaps.
This enduring activity will explore the management of moderate-to-severe atopic dermatitis (AD) in pediatric and adolescent patients. Innovative whiteboard animations will review the mechanism of action of systemic therapies for AD and the impact of COVID-19 on treatment selection. A review of clinical trial data, guideline recommendations, and patient-specific factors that impact management decisions will help clinicians develop personalized treatment plans and improve patient outcomes.
This initiative aims to increase the Department of Veteran’s Affairs multidisciplinary care team’s knowledge of both the efficacy and safety data from clinical trials for patients with small-cell lung cancer and review the NCCN clinical practice guidelines to optimize the outcomes of patients.
This activity provides a snapshot of the growing impact of dengue fever in Puerto Rico and strategies for prevention. Featured topics of this program include the burden of dengue fever and clinical trial data of approved and emerging vaccines.
This CME program provides a comprehensive and up-to-date perspective on the evolving management of patients with inflammatory bowel disease (IBD). We will be discussing unmet needs in the current identification and management of IBD; identifying tools to assist with differential diagnosis, clinical assessment, and selection of effective therapies for IBD; and exploring the underlying pathophysiology of IBD and the role of JAK inhibition in modifying therapeutic outcomes.
This enduring program aims to provide clinicians and patients with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for individuals with CRSwNP. Our goal is to provide information that empowers clinicians and patients to speak openly about treatment decisions and improve the standard of care for patients with this challenging disease.
This educational activity has been designed for nephrology fellows to ensure recognition of CKD risk in patients with T2D, understand novel strategies for modifying CKD risk, and review the risk of other chronic complications of T2D. We aim to evaluate current strategies for the management of CKD in T2D using novel therapeutic agents that modify long-term clinical outcomes, including third-generation mineralocorticoid antagonists; describe current disparities in CKD care in T2D and strategies for integrating novel strategies in practice, including third-generation mineralocorticoid antagonists; and lastly to summarize safety data with novel agents in the management of CKD in T2D, including best practices for managing hyperkalemia with novel mineralocorticoid antagonists.
The online activity will address the need for novel therapeutic options, including updates on advances in regenerative medicine, for patient with complex perianal fistula associated with Crohn’s disease. Learners will evaluate the current burden of perianal fistula in Crohn’s disease, pathophysiology, and the characteristics of current and emerging mechanisms of therapy.
This TeleECHO activity was designed to help oncologists and the multidisciplinary care team personalize gastric cancer treatment based on biomarker testing and use targeted therapies for HER2 positive disease treatment beyond the first line.
This online educational activity targets essential elements of the pearls of diagnosis and management of patients with α-thalassemias. Enhance your ability to evaluate the genetic and molecular pathophysiology of the various members of the α-thalassemia family and associated clinical presentations by genotype, as well as the risks for acute and chronic complications. After the timely, accurate diagnosis of α-thalassemia is made, assess the utility of traditional management strategies and the impact of emerging disease-modifying pharmacotherapy for the management of patients with α-thalassemias.
This CME program has been designed for primary care clinicians, pharmacists, and diabetes educators who care for patients with diabetes as well as patient audiences to increase knowledge of the relationship of glucose variability (GV) and time in range (TIR) to macro- and microvascular outcomes; enhance the ability to explain the importance of continuous glucose monitoring (CGM) and various CGM metrics; and select among basal insulin formulations based on their impacts on TIR and GV.
This TeleECHO series has been designed for US-based rheumatologists, nurses, and allied healthcare professionals involved in the management of patients with rheumatoid arthritis (RA), to better interpret data from clinical trials supporting the efficacy, safety, and tolerability of JAK inhibitors (JAKi) with different mechanisms of action in patients with moderate-to-severe RA. This series will help health professionals incorporate new evidence-based management recommendations on the use of JAKi for patients with moderate-to-severe RA into clinical practice, and it also supports patient-centered multidisciplinary team-based approaches to the management of those patients with moderate-to-severe RA.
RELEASED DATE: October 03, 2022
EXPIRATION DATE: October 03, 2023
This enduring activity will help health care professionals better evaluate the potential for multi-cancer early detection technologies to improve cancer detection and therapeutic outcomes in cancer care; analyze the accuracy for application of multicancer early detection technologies and ongoing trials; and choose appropriate patient populations that may be candidates for screening with multicancer early detection technologies and ensure clinicians are ready to discuss the meaning of test results with patients.
RELEASE DATE: October 05, 2022
EXPIRATION DATE: October 05, 2023
This program will discuss the pathogenesis of prostate cancer, the differences in mechanisms of action between the first- and second-generation anti-androgen drugs for prostate cancer, and identifying patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at elevated risk for metastasis, and management in order to reduce risk.
RELEASE DATE: October 06, 2022
EXPIRATION DATE: October 06, 2023
This educational activity will explore best practices to ensure prompt and accurate diagnosis of COVID-19 infection and the provision of outpatient care for patients with COVID-19 while incorporating shared decision-making principles and addressing disparities in care.
RELEASED DATE: October 06, 2022
EXPIRATION DATE: October 06, 2023
This program will discuss tumorigenesis in advanced non-small cell lung cancer (NSCLC) and the mechanism of actions of checkpoint inhibitors, the latest clinical data describing the efficacy and safety of first-line use of PD-1 inhibitor therapy, alone and in combination, and the use of immunotherapy in the first-line treatment of NSCLC with no actionable mutations.
RELEASE DATE: October 07, 2022
EXPIRATION DATE: October 07, 2023
This TeleECHO session will explore the management of patients with metastatic colorectal cancer (mCRC) through a short, didactic presentation and interactive case studies. Faculty will review strategies on personalizing the selection of treatment options based on molecular testing; and discuss the management of adverse events with targeted treatments for BRAF V600-mutant mCRC.
RELEASED DATE: October 10, 2022
EXPIRATION DATE: October 10, 2023
RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023
RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023
RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023
RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023
This online educational program focuses on the latest data on mealtime insulin in patients with type 2 diabetes mellitus. In this program, clinicians will address appropriate treatment intensification strategies in consideration of patient-related factors, the latest clinical data, and key parameters for monitoring clinical response to mealtime insulin. Through this program, clinicians will improve their level of comfort with initiating mealtime insulins to optimize glycemic outcomes, including in underserved populations. Innovative learning strategies will reinforce the latest best practices to support clinician and patient understanding of the latest strategies in glycemic management.
RELEASED DATE: October 14, 2022
EXPIRATION DATE: October 14, 2023
This enduring activity has been designed for healthcare professionals involved in the management of patients with psoriasis to improve knowledge of the function of TYK2 in psoriasis; awareness of clinical profiles of emerging TYK2 inhibitors; their ability to discern the potential place of TYK2 inhibitors in current treatment algorithms; and the adoption of shared decision-making with patients.
RELEASED DATE: October 25, 2022
EXPIRATION DATE: October 25, 2023
This activity will address the challenges faced by clinicians in managing older patients with T2DM. Participants will be equipped with an enhanced ability to apply current guideline recommendations and clinical data to management plans, personalize diabetes treatment for older adults in long-term care facilities and in the community, and gain greater knowledge of the rationale for using fixed ratio combinations of basal insulin and GLP-1 receptor agonists in older adults with T2DM.
RELEASE DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023
This activity features education regarding the links between obesity and diabetes, the role of the incretin system in these metabolic disorders, and use of incretin therapies to manage diabetes-related obesity.
RELEASED DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023
This enduring activity is designed to help HCPs improve their ability to evaluate the risk of pneumococcal infection from a population perspective and consider the importance of various serotypes in managing population health; assess clinical data and specific data with pneumococcal serotypes to determine treatment options in the context of guidelines; and to apply best practices in implementing pneumococcal vaccination schedules to improve health outcomes.
RELEASED DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023
This enduring activity is faculty-led didactic and case-based interactive activities focusing on the management of patients with Type 2 diabetes and obesity. This CME program has been designed to help clinicians recognize overweight/obesity as an important treatment target; utilize guidelines and clinical data on the use of incretin therapies for treatment intensification; and implement shared decision making to better engage patients and personalize care.
RELEASED DATE: October 27, 2022
EXPIRATION DATE: October 27, 2023
This activity discusses the care of patients hospitalized with SARS-CoV-2 infection. The program will address the burden of COVID-19 in the US as well as the currently circulating strains. The program is designed to help clinicians integrate the latest treatment guidelines and management strategies for this patient population into their practice. The program will present the results of the latest clinical trials of novel therapies for COVID 19 to inform clinicians’ choice of therapy for patients hospitalized with SARS-CoV-2 to reduce the risk of mortality.
RELEASED DATE: November 1, 2022
EXPIRATION DATE: November 1, 2023
This enduring TeleECHO podcast will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas (NMSCs). Over the course of this activity there will be discussion of the data from clinical trials assessing the clinical profiles of new systemic therapies with different mechanisms of action for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation; integrating methods for identifying and managing side effects associated with new systemic therapies for the treatment of patients with advanced NMSCs into routine clinical practice; categorizing the types of patients with unresectable NMSCs who may benefit from new systemic therapies for the treatment of advanced NMSCs; and lastly enhancing patient management including care coordination through participation in interdisciplinary care teams for those with advanced NMSCs failing or not amenable to surgery or radiation.
RELEASED DATE: November 3, 2022
EXPIRATION DATE: November 3, 2023
This educational activity will explore the appropriate place in the therapy paradigm for immunotherapy in patients with head and neck cancer, as well as managing adverse effects of immunotherapies.
RELEASED DATE: November 04, 2022
EXPIRATION DATE: November 04, 2023
RELEASED DATE: November 4, 2022
EXPIRATION DATE: November 4, 2023
RELEASED DATE: March 16, 2023
EXPIRATION DATE: March 16, 2024
The DETECT Immersive Simulation experience provides up-to-date information on the diagnosis and management of mild cognitive impairment and Alzheimer’s disease (AD) targeted to specific specialties. The program uses a case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.
RELEASED DATE: March 20, 2023
EXPIRATION DATE: March 20, 2024
This podcast will discuss the burden of illness and the burden of treatment associated with primary immune deficiency disorder (PIDD). Additionally, the podcast will address the intersectionality of having PIDD and belonging to an underserved/minority community.
RELEASED DATE: March 20, 2023
EXPIRATION DATE: March 20, 2024
RELEASED DATE: March 20, 2023
EXPIRATION DATE: March 20, 2024
This activity is designed to meet the educational needs of U.S.-based community healthcare providers who care for patients with AD, including primary care clinicians, neurologists, geriatricians, geriatric psychologists, psychiatrists, pharmacists, and managed care professionals.
This enduring activity will explain immune dysfunction and the pathogenesis of moderate-to-severe asthma, currently available and emerging targeted therapies used for moderate-to-severe asthma, and the usefulness and application of guidelines and biomarkers to guide treatment selection for this disease.
RELEASED DATE: March 22, 2023
EXPIRATION DATE: March 22, 2024
This program will focus on the application and implementation of multicancer early detection (MCED) testing in primary care. The content will review the basics of MCED technology and how it improves cancer detection; describe which patients may be candidates for this type of screening; discuss what tests are available; and review how these tests can be used in primary care.
RELEASED DATE: March 23, 2023
EXPIRATION DATE: March 23, 2024
These online enduring podcasts focus on the role of GLP-1 receptor agonists in the care of patients with type 2 diabetes, including but not limited to, the glycemic and extra-glycemic effects and strategies to avoid adverse events of GLP-1 receptor agonists while enhancing the patient/provider partnership using a shared decision-making approach to the selection of GLP-1 receptor agonists.
RELEASED DATE: February 27, 2023
EXPIRATION DATE: March 23, 2024
This virtually live / enduring activity has been designed to meet the educational needs of community-based and academic medical oncologists and other healthcare professionals, including oncology nurses, pulmonary oncologists, pharmacists, and nurse practitioners to ensure an up-to-date understanding of the latest data in the management of NSCLC through checkpoint inhibition strategies. We aim to help HCPs better consider immunopathologic factors in the pathogenesis of NSCLC and strategies for targeting NSCLC based on appropriate application of clinical biomarkers; recognize the latest clinical trial updates concerning front-line use of immuno-oncology strategies in NSCLC and, lastly, to evaluate the latest biomarkers for selection of therapies for the management of NSCLC.
RELEASED DATE: December 21, 2022
EXPIRATION DATE: March 23, 2024
The educational activity is designed to meet the educational needs of healthcare professionals to address disparities of education within the Veterans Affairs Health-care system specifically chronic idiopathic constipation (CIC). We aim to help HCPs within the VA system increase their ability to: evaluate current best practices in the diagnosis of CIC in consideration of pathophysiology and therapeutic mechanisms; recognize current real-world and clinical trial evidence regarding the efficacy and safety of available CIC therapies; and summarize current strategies for effective implementation of shared decision making in meeting patient-centered therapeutic goals.
RELEASED DATE: March 27, 2023
EXPIRATION DATE: March 27, 2024
This case-based enduring activity is designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma.
RELEASED DATE: March 27, 2023
EXPIRATION DATE: March 27, 2024
This TeleECHO series is designed to update clinicians who care for patients at risk for and with COVID-19 with the most up-to-date guidelines on the prevention, diagnosis, and management of patients in the outpatient setting.
RELEASED DATE: March 30, 2023
EXPIRATION DATE: March 30, 2024
This TeleECHO session explores the utility of potassium-restricted diets in patients with hyperkalemia based on the most recent studies. It also reviews the role of potassium binders in managing hyperkalemia.
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
This program uses a unique, interactive approach to providing the most up-to-date information on the use of systemic therapies and multidisciplinary care in atopic dermatitis (AD).
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
This enduring activity has been designed to meet the educational needs of healthcare providers in the Department of Veterans Affairs, including psychiatrists involved in the management of patients with schizophrenia. We aim to help HCPs within the VA system assess the clinical benefits and disadvantages associated with dopamine-modulating antipsychotic medications approved for the management of schizophrenia and also interpret data from clinical trials assessing the clinical profiles of new and emerging therapies for the management of schizophrenia that have unique targets and mechanisms of action.
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
This innovative and engaging symposium is an animated simulation challenge, which will assist Healthcare providers to utilize assessment tools to evaluate disease burden and severity; compare and contrast systemic treatment options for the management of moderate-to-severe atopic dermatitis (AD); and develop proactive treatment plans that manage signs and symptoms, minimize disease flares, and improve quality of life in pediatric and adult patients with AD.
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
This educational Microlearning Snapshot enduring activity focuses on the importance of genes in the pathogenesis of inherited and acquired retinal diseases and how they can be leveraged in gene therapy for the management of various retinal diseases. Additional considerations regarding risk/benefit profile, durability, feasibility and application as well as emerging advances in anti-vascular endothelial growth factor (anti-VEGF) treatment are also explored for impact on overcoming barriers related to treatment burden and adherence.
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
Following the posting of this activity tirzepatide has received FDA approval for use in adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
This educational activity is intended for U.S. primary care physicians, nurses, NPs, PAs, dieticians and RDs who manage patients with obesity.
RELEASED DATE: March 31, 2023
EXPIRATION DATE: March 31, 2024
The enduring DETECT Clinical Conversations Exchange connects specialists with community health care providers to provide education on best practices for managing patients with early cognitive impairment and Alzheimer’s disease. The program uses a case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.
RELEASED DATE: April 03, 2023
EXPIRATION DATE: April 03, 2024
The enduring DETECT Clinical Conversations Exchange connects specialists with community health care providers to provide education on best practices for managing patients with early cognitive impairment and Alzheimer’s disease. The program uses a case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.
RELEASED DATE: April 03, 2023
EXPIRATION DATE: April 03, 2024
This activity has been designed for healthcare professionals who care for patients with small cell lung cancer (SCLC). The program serves to improve HCP’s knowledge of relevant efficacy and safety data concerning second-line treatment options for patients with extensive-stage SCLC; comprehension of clinical trial evidence behind current guideline recommendations; and their ability to apply second-line efficacy and safety data to small-cell lung cancer care.
RELEASED DATE: April 07, 2023
EXPIRATION DATE: April 07, 2024
This enduring seeks to improve HCPs ability appropriately incorporate new systemic therapies for the treatment and management of patients with advanced NMSCs.
RELEASED DATE: April 07, 2023
EXPIRATION DATE: April 07, 2024
Med Learning Group hosted this 3D Satellite Summit Meeting that contained innovative and engaging animations in partnership with EHA. This enduring program has 2 highly regarded faculty speakers and contains 2.0 hours of content. The educational activity allows for a high level of interactivity as there will be breaks in the faculty presentations where the learners utilize animations with interactive question/answer sessions that the faculty will review with the audience. In addition, we are partnering with the Public Health Foundation (PHF) for program awareness; they will broadcast the meeting through their network healthcare providers.
RELEASED DATE: April 7, 2023
EXPIRATION DATE: April 7, 2024
This enduring summit meeting educational activity is designed for oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team with the goal of increasing their: recognition of the role of bispecific antibodies in management of lymphoma, as well as clinical trial opportunities for patients with B-cell lymphomas; confidence discussing clinical trial outcomes with bispecific antibodies in lymphoma; awareness of specific adverse events associated with anti-CD20 therapies; and their recognition of multidisciplinary best practices for management of adverse events with targeted therapies for lymphoma.
RELEASED DATE: April 07, 2023
EXPIRATION DATE: April 07, 2024
This enduring activity will focus on the application and implementation of multicancer early detection (MCED) testing in primary care. The content will review the basics of MCED technology and how it improves cancer detection; describe which patients may be candidates for this type of screening; discuss what tests are available; and review how these tests can be used in primary care.
RELEASED DATE: April 10, 2023
EXPIRATION DATE: April 10, 2024
This enduring activity will increase the target HCP’s understanding of new immune therapies and clinical trial data for treating patients with advanced NMSCs; ability to identify and manage side effects associated with new systemic therapies for treating patients with advanced BCC; and ability to coordinate care and improve outcomes for patients with advanced NMSCs failing or not amenable to surgery or radiation.
RELEASED DATE: April 10, 2023
EXPIRATION DATE: April 10, 2024
This enduring HoloVision™ activity is an online program designed to advance healthcare practitioners’ ability to: evaluate mechanisms of action in multiple myeloma; examine the rationale for earlier-line use of CAR T-cell therapy in multiple myeloma; summarize the latest efficacy and safety data with CAR T-cell therapy; consider the design of current clinical trials in early-relapsed high-risk multiple myeloma; and formulate strategies for sequencing of CAR T-cell therapy, including adverse event management.
RELEASED DATE: April 14, 2023
EXPIRATION DATE: April 14, 2024
This activity is designed to meet the educational needs of U.S.-based community healthcare providers who care for patients with AD, including primary care clinicians, neurologists, geriatricians, geriatric psychologists, psychiatrists, pharmacists, and managed care professionals.
RELEASED DATE: April 20, 2023
EXPIRATION DATE: April 20, 2024
This Enduring of the DETECT Grand Rounds connects specialists with on-the-ground community HCPs to educate them on best practices for managing patients with early cognitive impairment and Alzheimer’s disease. The program uses an animated, case-based, interactive format designed to enhance clinician knowledge and improve their confidence in treating this population.
RELEASED DATE: April 19, 2023
EXPIRATION DATE: April 19, 2024
The educational activity focuses on the role of GLP-1 receptor agonists in the care of patients with type 2 diabetes, including but not limited to, the glycemic and extra-glycemic effects and strategies to avoid adverse events of GLP-1 receptor agonists while enhancing the patient/provider partnership using a shared decision-making approach to the selection of GLP-1 receptor agonists.
RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024
This educational Microlearning Snapshot enduring activity aims to increase the target clinicians’ ability to recognize racial, ethnic and sex variations in the prevalence and disease course of ocular diseases, as well as factors that contribute to health disparities, exacerbate underutilization of care, and impact clinical trial recruitment. Learn more about the importance of diversity in clinical research and acquire tactics to encourage underrepresented minority enrollment in clinical trials.
RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024
This podcast series aims to increase the target clinicians’ awareness of factors that contribute to health disparities in patients with ocular disorders and potential barriers to care. Learn about leadership style and why increasing diversity within the eye care workforce is essential to patient care along with strategies for increasing representation. Enhance appreciation of the need for diverse representation in research in clinical trials, as this can lead to better access, and acquire tactics to increase underrepresented minority enrollment in clinical trials.
RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024
This enduring program focuses on providing Veterans Affairs clinicians with updates in the management of advanced melanoma, including consideration of anti-LAG-3 antibodies. It also provides an overview of the latest trials considering anti-LAG-3 antibodies for the management of advanced melanoma, and updates on immunotherapy approaches in clinical practice.
RELEASED DATE: April 25, 2023
EXPIRATION DATE: April 25, 2024
This enduring activity will increase awareness of the mechanisms of action and clinical profiles of new systemic therapies for the treatment of patients with advanced NMSCs failing or not amenable to surgery or radiation; increase ability to identify and manage side effects associated with new systemic therapies for the treatment of patients with advanced NMSC; identify patients with NMSCs who may benefit from new systemic therapies for the treatment of advanced NMSCs; and finally, better coordinate care and improve outcomes for patients with advanced NMSCs failing or not amenable to surgery or radiation.
RELEASED DATE: April 27, 2023
EXPIRATION DATE: April 27, 2024
This Clinical Conversation Exchange educational online activity focuses on increasing the target clinicians’ awareness of racial, ethnic, and sex variations in the prevalence and disease course of ocular diseases, along with other factors that contribute to underutilized care. Learn strategies to increase diversity in the eyecare workforce and how this can improve access to care. Enhance understanding of the importance of more diverse representation in clinical research and acquire tactics to encourage higher enrollment of underrepresented minorities in clinical trials.
RELEASED DATE: April 28, 2023
EXPIRATION DATE: April 28, 2024
This enduring activity has been designed for healthcare professionals who manage patients with obesity. The program will seek to help HCPs increase their recognition of obesity as a disease; recognize the burden of comorbidities associated with obesity; and increase their ability to apply clinical data to guide treatment selection for obesity. Learners will also recognize the need for implementing guideline-based management of obesity across providers and increase their comfort with the integration of weight reduction pharmacotherapy.
RELEASED DATE: April 10, 2023
EXPIRATION DATE: April 28, 2024
Through case-based education, this enduring TeleECHO activity will discuss unmet needs in Inflammatory Bowel Disease (IBD) management with considerations for modification of clinical outcomes with novel therapies; evaluate current guidelines for differential diagnosis, clinical assessment, and choice of therapeutic options in IBD; and provide clinicians with better understanding of the importance of JAK/STAT signaling in inflammatory conditions.
RELEASED DATE: May 01, 2023
EXPIRATION DATE: May 01, 2024
This podcast episode will focus on the overview of the disease state and talk about initial management strategies for patients with relapsed/refractory multiple myeloma.
RELEASED DATE: May 01, 2023
EXPIRATION DATE: May 01, 2024
This podcast focuses on current guidelines for diagnosing COVID-19 and why people with certain underlying conditions face a higher risk of hospitalization and death if they get infected.
RELEASED DATE: May 05, 2023
EXPIRATION DATE: May 05, 2024
This enduring activity will provide HCPs with knowledge and context around the science and technology behind MCED testing and the potential for improved clinical outcomes with earlier detection; tools to determine the accuracy of MCED tests and how to communicate results to patients; and tips on best practices for overcoming patient and physician barriers to MCED testing for better integration in primary care.
RELEASED DATE: May 10, 2023
EXPIRATION DATE: May 10, 2024
This program uses an immersive, specialty-based approach to explore the current understanding of COVID risk assessment, diagnosis, and outpatient treatment.
RELEASED DATE: May 12, 2023
EXPIRATION DATE: May 12, 2024
The goal of this enduring activity series is to help HCPs ensure optimal patient outcomes in outpatient management of COVID-19 infection by increasing understanding of the need for early diagnosis and intervention for patients at high risk for progression to severe COVID-19.
RELEASED DATE: May 18, 2023
EXPIRATION DATE: May 18, 2024
This COVID-19 Snapshot series provides a comprehensive and up-to-date perspective on the ever-changing outpatient management of patients with COVID-19.
RELEASED DATE: May 19, 2023
EXPIRATION DATE: May 19, 2024
This case-based enduring activity will focus on the epidemiology, pathophysiology, diagnosis, and treatment of ulcerative colitis (UC), and aims to result in clinical improvement in the management of UC through an increased understanding of how UC with bowel urgency affects quality of life and clinical outcomes in patients; and an increased ability to apply the latest clinical data on new and emerging agents, and their impact on bowel urgency, to treatment decision making.
RELEASED DATE: May 30, 2023
EXPIRATION DATE: May 30, 2024
This online program will provide clinicians who care for people with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.
RELEASED DATE: May 30, 2023
EXPIRATION DATE: May 30, 2024
This enduring activity will increase the target clinician’s knowledge base on new systemic immune therapies for the treatment of patients with non-melanoma skin cancer (NMSC); enhance their ability to identify and manage side effects associated with new immunotherapies for the treatment of patients with advanced basal cell carcinoma or cutaneous squamous cell carcinoma; and improve their ability to coordinate care and cooperation across the multidisciplinary care team to optimize outcomes in patients with NMSC.
RELEASED DATE: May 31, 2023
EXPIRATION DATE: May 31, 2024
This podcast episode will focus on the overview of the disease state and talk about initial management strategies for patients with relapsed/refractory multiple myeloma.
RELEASED DATE: May 01, 2023
EXPIRATION DATE: May 31, 2024
This activity is designed to meet the educational needs of U.S.-based community healthcare providers who care for patients with AD, including primary care clinicians, neurologists, geriatricians, geriatric psychologists, psychiatrists, pharmacists, and managed care professionals.
RELEASED DATE: June 01, 2023
EXPIRATION DATE: June 01, 2024
This Enduring of the DETECT Summit connects specialists with community healthcare providers to provide education on best practices for managing patients with early cognitive impairment and Alzheimer’s disease (AD). The program uses a case-based format designed to enhance clinician knowledge and improve their confidence in treating this population.
RELEASED DATE: June 01, 2023
EXPIRATION DATE: June 01, 2024
This enduring activity focuses on the use of next-generation therapies such as gene therapy, biosimilars, advanced delivery systems, artificial intelligence, and advancements in pharmacological treatments, including new molecular targets and therapeutic formulations for the management of patients with diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion. Listen to a retina expert explain the rationale behind these new therapies, as well as the clinical trial data regarding their safety, efficacy, and mechanisms of action to expand treatment options and potentially improve visual outcomes in patients with retinal vascular conditions.
RELEASED DATE: June 08, 2023
EXPIRATION DATE: June 08, 2024
This enduring activity is designed aims to help HCPs reduce time to diagnosis in patients with suspected NTM-LD, individualize treatment selection for patients with NTM-LD in frontline and refractory settings based on clinical guidelines and patient characteristics, evaluate the role of amikacin liposome inhalation suspension (ALIS) in the treatment of patients with NTM-LD, and optimize strategies to avoid and manage the adverse effects of antibiotic therapy inpatients with NTM-LD and facilitate the completion of therapy.
RELEASED DATE: June 09, 2023
EXPIRATION DATE: June 09, 2024
This podcast will discuss the risks of severe disease in patients with obesity who develop COVID-19.
RELEASED DATE: June 09, 2023
EXPIRATION DATE: June 09, 2024
This enduring activity will enhance clinicians’ ability to identify evidence-based strategies to inform prompt diagnosis, treatment selection and adjustments and reduce the occurrence of exacerbations; improve the implementation of individualized treatment plans that include patient communication, education, and shared decision-making; and design treatment regimens that incorporate guideline recommendations and emerging clinical trial data.
RELEASED DATE: June 12, 2023
EXPIRATION DATE: June 12, 2024
This online program is designed to help primary care clinicians who manage patients who have or are at risk for diabetic eye disease. Learn about the importance of early detection and recommended screening guidelines, how to identify patients at higher risk for diabetic eye disease, and multidisciplinary management options to help patients with diabetes preserve vision.
RELEASED DATE: June 12, 2023
EXPIRATION DATE: June 12, 2024
This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about biomarkers that guide treatment selection, novel immunotherapy treatment strategies, and the critical role of multidisciplinary management to individualize care in melanoma.
RELEASED DATE: June 15, 2023
EXPIRATION DATE: June 15, 2024
This enduring activity takes learners on a compelling journey in managing chronic graft-versus-host disease (cGVHD) by explaining the evidence-based diagnostic criteria for cGVHD for prompt diagnosis; discussing the clinical safety and efficacy data of recently approved and investigational therapeutic agents, and finally, developing strategies to create treatment plans that address the psychosocial impact of disease and prioritize improvement in quality of life. Learners are invited to explore challenging aspects of this condition with the goal of informing selection of the most appropriate treatment regimens targeting disease etiopathogenesis. This immersive experience highlights the importance of early recognition in the effective management of cGVHD.
RELEASED DATE: June 16, 2023
EXPIRATION DATE: June 16, 2024
This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immuno-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in Basal Cell Carcinoma (BCC).
RELEASED DATE: June 22, 2023
EXPIRATION DATE: June 22, 2024
This enduring activity will inform clinicians of the rationale for use of immunotherapy in non-melanoma skin cancer (NMSC), specifically keratinocyte carcinomas, and how immunotherapy may be a therapeutic adjunct to treatment of NMSCs. Key topics that will be covered through didactic and case-based discussions include pathophysiology, mechanisms of tumor cell dissemination and post-surgical recurrence, emerging use of immune checkpoint inhibition in the neo-adjuvant setting of cutaneous squamous cell carcinoma, as well as efficacy and safety data from studies of immunotherapy in patients with either advanced basal cell or advanced cutaneous squamous cell carcinomas.
RELEASED DATE: June 29, 2023
EXPIRATION DATE: June 29, 2024
This enduring educational activity will explore the management of advanced non-small cell lung cancer (NSCLC). The presentation including animations and case studies will discuss treatment options and management of the disease and will assess clinical trial data regarding efficacy and safety.
RELEASED DATE: June 30, 2023
EXPIRATION DATE: June 30, 2024
This educational enduring program will help healthcare professionals to optimize patient outcomes for those with advanced melanoma without actionable melanoma mutations. Specifically, the programming will improve clinicians’ knowledge of the latest data concerning appropriate assessment of melanoma from a clinical pathologic view and familiarize them with current updates with single-agent and combination therapy in advanced melanoma across settings of care, while preparing them to best manage adverse events across these therapies.
RELEASED DATE: June 30, 2023
EXPIRATION DATE: June 30, 2024
This educational program will help healthcare providers to better examine clinical trials data supporting the use of new systemic immunotherapies for the treatment of patients with advanced nonmelanoma skin cancers (NMSCs), failing or not amenable to surgery or radiation; describe risk-assessment of patients with NMSCs who may derive greater benefit from new systemic therapies as opposed to Mohs surgery; and review the coordination and collaboration of multidisciplinary team members in the management of patients with advanced NMSCs failing or not amenable to surgery or radiation.
RELEASED DATE: June 30, 2023
EXPIRATION DATE: June 30, 2024
This enduring program will provide clinicians who care for patients with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.
RELEASED DATE: July 07, 2023
EXPIRATION DATE: July 07, 2024
This enduring will focus on strategies to identify CKD risk in patients with T2D and familiarity with novel strategies for modifying CKD risk and the risk of other chronic complications of T2D.
RELEASED DATE: July 12, 2023
EXPIRATION DATE: July 12, 2024
This educational virtual pathways program will help healthcare providers to optimize immunopathological assessment of melanoma, particularly in consideration of patterns of resistance. Specifically, the programming will improve clinicians’ knowledge of the latest data on combination therapies in advanced melanoma across settings of care, while preparing them to manage adverse events with these combination therapies for advanced melanoma.
RELEASED DATE: July 12, 2023
EXPIRATION DATE: July 12, 2024
This enduring activity will address methodology to specifically support healthcare professionals charged with the care of pediatric patients with influenza so that they can better expedite an accurate influenza diagnosis, evaluate and appropriately incorporate antiviral agents for the pediatric population inclusive of postexposure prophylaxis, and recognize the full range of therapeutic tools at their disposal to care for pediatric patients.
RELEASED DATE: July 12, 2023
EXPIRATION DATE: July 12, 2024
This virtually live educational activity focuses on leveraging targetable mutations for cancer-directed therapy through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in Non-Hodgkin’s Lymphoma.
RELEASED DATE: July 20, 2023
EXPIRATION DATE: July 20, 2024
This enduring activity has been designed to help gastroenterologists and advanced practitioners who treat patients with ulcerative colitis distinguish histologic healing as a treatment target; assess data on the association between histologic remission in ulcerative colitis and patient outcomes; and utilize appropriate tools for assessing histologic activity in patients with ulcerative colitis to guide treatment and monitoring plans.
RELEASED DATE: March 23, 2023
EXPIRATION DATE: July 21, 2024
This activity is designed to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.
RELEASED DATE: June 27, 2023
EXPIRATION DATE: June 27, 2024
This educational activity is designed for psychiatrists, nurse practitioners, physician assistants, nurses, and other healthcare professionals and focuses on the management of patients with major depressive disorder (MDD), with the goal of reaching full remission in patients showing an adequate response to first-line therapies utilizing patient-centered, shared decision-making management strategies.
RELEASED DATE: July 27, 2023
EXPIRATION DATE: July 27, 2024
The Virtual Pathway activity will inform clinicians of the rationale for use of immunotherapy in cutaneous squamous cell carcinoma (cSCC), including the reasoning behind investigations of its use in the neoadjuvant or adjuvant settings. Through this interactive experience that incorporates didactic presentations, illustrative animations, and case-based discussion, clinicians will be exposed to current perspectives on the pathophysiology of early cSCC, how immunotherapy before and/or after surgery may improve outcomes, and available data from clinical study of neoadjuvant immunotherapy for cSCC.
RELEASED DATE: July 28, 2023
EXPIRATION DATE: July 28, 2024
This enduring activity is designed for academic and community medical oncologists, pathologists, nurse practitioners, physician assistants, and pharmacists who care for patients with non-small cell lung cancer (NSCLC). We aim to increase the target healthcare provider’s ability to: describe the role of TROP2 in the clinicopathophysiology of NSCLC and its role in treatment as a targetable protein; assess the clinical trials data for TROP2-targeted therapy, in the second-line, for those patients with relapsed/refractory NSCLC; and identify strategies for managing adverse events, patient and treatment selection that include TROP2-directed antibody-drug conjugates.
RELEASED DATE: August 01, 2023
EXPIRATION DATE: August 01, 2024
In this enduring program, we will discuss how healthcare providers within the Department of Veterans Affairs can improve their treatment of patients with acute myeloid leukemia (AML) by providing updates on key biological features and biomarkers of AML to inform patient assessment with novel therapies. In addition, we will review the latest data on AML management and challenges in effectively communicating the rationale for therapeutic decisions with patients and caregivers.
RELEASED DATE: August 02, 2023
EXPIRATION DATE: August 02, 2024
This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in cutaneous squamous cell carcinoma.
RELEASED DATE: August 10, 2023
EXPIRATION DATE: August 10, 2024
RELEASED DATE: August 11, 2023
EXPIRATION DATE: August 11, 2024
This educational Virtual Pathways enduring activity focuses on the key characteristics and management strategies of Rett Syndrome (RTT). Learn more about the genetic underpinnings and pathophysiology of RTT, distinctive clinical manifestations to aid diagnosis, and new therapeutic options that may help improve the disease burden of RTT. Through expert case study presentation, learners will be guided on ways to incorporate strategies for providing a timely and accurate diagnosis of RTT into clinical practice, as well as to evaluate the clinical profiles of approved and emerging therapeutic options for treatment of RTT.
RELEASED DATE: August 11, 2023
EXPIRATION DATE: August 11, 2024
This educational activity will explore the intersection of obesity and COVID-19, highlighting the increased risk of severe COVID that people with obesity face, and outpatient opportunities to reduce that risk.
RELEASED DATE: August 11, 2023
EXPIRATION DATE: August 11, 2024
This enduring activity is a faculty-led didactic and case-based interactive activity designed to facilitate the implementation of a holistic approach to simultaneously address weight management and glycemic control in patients with type 2 diabetes. Participants will gain knowledge of the rationale for a weight-centric approach to type 2 diabetes management; use guidelines and clinical data to select pharmacological agents that facilitate both weight management and glycemic control; and implement shared decision making to better engage patients and personalize care.
RELEASED DATE: August 14, 2023
EXPIRATION DATE: August 14, 2024
This enduring activity will explore the management of patients with newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) through didactic slide review, case study discussion, and a robust Q&A session. This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, relapsed/refractory, and secondary AML. A summary of approaches to treatment-related adverse event recognition and mitigation will also be discussed.
RELEASED DATE: August 14, 2023
EXPIRATION DATE: August 14, 2024
This educational activity is designed to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC. We aim to discuss both the VA oncology clinical pathways and oncology precision program to guide personalized NSCLC care; evaluate immune checkpoint monotherapy clinical findings in the front-line treatment of patients with advanced NSCLC without targetable mutations; and examine the trials data for PD-1 inhibitor/chemotherapy combinations in the front-line management of patients with advanced NSCLC and no targetable mutations.
RELEASED DATE: August 15, 2023
EXPIRATION DATE: August 15, 2024
RELEASED DATE: July 14, 2023
EXPIRATION DATE: August 15,2024
This podcast episode will focus on the overview of the disease state, strategies for employing multidisciplinary assessments for risk of progressive disease, and the role of CAR-T cell therapy in managing relapsed/refractory diffuse large B-cell lymphoma.
RELEASED DATE: August 11, 2023
EXPIRATION DATE: August 11, 2024
This educational activity is focused on understanding the prevalence and management of uterine fibroids (UF). Using a combination of Whiteboard Preceptorship, podcast episodes, and personalized posters, participants will learn about the various treatment options for UF, including medical and surgical interventions. The program will dive deeper into novel clinical approaches to UF treatment, including combination therapies with gonadotropin-releasing hormone antagonists for UF management. Additionally, the program will emphasize the importance of, and steps for, shared decision-making in short- and long-term management of UF.
RELEASED DATE: August 18, 2023
EXPIRATION DATE: August 18, 2024
This program will provide clinicians who care for people with chronic lymphocytic leukemia and mantle cell leukemia with important updates about current and future management of the diseases. It includes two animations and case study discussions.
RELEASED DATE: August 21, 2023
EXPIRATION DATE: August 21, 2024
This enduring activity has been designed to improve the diagnosis and management of pediatric patients with influenza. Health care providers will gain proficiency in providing a timely and definitive influenza diagnosis for pediatric patients by using point-of-care testing methodologies, selecting among approved influenza antiviral agents, and using antiviral treatment for influenza postexposure prophylaxis as appropriate in pediatric patients. Point-of-care tools and resources will assist with reflection, patient education, and collaboration.
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about potential immune targets, systemic treatment strategies, and optimizing multidisciplinary management to individualize care in multiple myeloma.
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological advancements that can help with timely diagnosis and/or effective interval monitoring of nAMD, discuss the benefits and treatment burdens of conventional anti-vascular endothelial growth factor (VEGF) therapies, and compare the safety, efficacy, and durability of established and emerging therapies for patients with nAMD.
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
This enduring innovative educational activity will be specifically designed to meet the unique educational needs of US-based neurologists, ophthalmologists, neuro-ophthalmologists, optometrists, pharmacists, emergency medicine clinicians, nurses, nurse practitioners, and physician’s assistants who diagnose and manage patients with neuromyelitis optica spectrum disorders (NMOSD). Through this thoughtfully designed and pedagogically effective programming, we aim to help healthcare providers: assess the burden of NMOSD on patients regarding HRQoL and disability, review the role of AQP4 in NMOSD and its implications for treatment selection, identify and review the potential biomarkers in the CNS of patients with NMOSD, and evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with NMOSD.
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
In this activity we will discuss the relevance of specific genetic and molecular markers in Chronic Lymphocytic Leukemia (CLL), review the current evidence concerning the application of minimal residual disease (MRD) monitoring, and emerging strategies and combinations for CLL management in first-line and relapsed/refractory settings. Finally, we will examine the potential adverse events associated with CLL therapeutics, including specific considerations with combination therapies.
RELEASED DATE: September 08, 2023
EXPIRATION DATE: September 08, 2024
This enduring activity focuses on individualizing therapy for the treatment of diabetic macular edema (DME). Providers will learn about the safety, efficacy, and durability of established and emerging DME therapies, as well as technological updates that can be used to facilitate patient screening, monitoring, and treatment interval decision-making. This activity uses a unique documentary approach to share a patient story along with commentary from a retinal disease expert.
RELEASED DATE: September 08, 2023
EXPIRATION DATE: September 08, 2024
This educational activity is designed to meet the identified needs of U.S.-based family medicine practitioners, pulmonologists, respiratory technicians, and other health care providers involved in the care of adult and pediatric patients with moderate-to-severe asthma.
This enduring program focuses on relapsed/refractory multiple myeloma (R/RMM) and aims to help VA health care professionals recognize overexpressed antigens that can serve as immunologic targets on malignant multiple myeloma plasma cells and how bispecific antibodies can be leveraged as targeted therapy in R/RMM.
RELEASED DATE: September 25, 2023
EXPIRATION DATE: September 25, 2024
This enduring educational activity focuses on leveraging targetable mutations for cancer-directed therapy, through evaluating approaches to tumor assessment as well as the latest developments in novel targeted and immune-therapeutic approaches. Learn more about biomarkers that guide treatment selection, novel immunotherapy treatment strategies, and the critical role of multidisciplinary management to individualize care in non-small cell lung cancer.
RELEASED DATE: September 28, 2023
EXPIRATION DATE: September 28, 2024
This program addresses current evidence-based perspectives in first-line management of advanced non-small cell lung cancer (NSCLC) in the first-line setting based on biomarkers, tumor histology, and patient-specific factors. By analyzing current clinical trial data and patient subgroups, clinicians will gain an understanding of therapeutic strategies, including checkpoint inhibitor monotherapy and checkpoint inhibitors in combination with chemotherapy. Given updates in the early-line management of NSCLC, it is crucial for multidisciplinary health care professionals to maintain awareness of novel combinations and potential adverse events associated with therapy, including immune-related adverse events. This program will emphasize best practices in multidisciplinary management, adverse event monitoring, and ongoing care to optimize therapeutic outcomes.
RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024
This enduring activity focuses on individualizing therapy for the treatment of diabetic macular edema (DME) based on patient-, disease-, and treatment-related factors. Providers will learn about technological advancements that can help with timely diagnosis and/or effective interval monitoring of DME. Listen to a retina expert discuss the benefits and treatment burdens of conventional anti-vascular endothelial growth factor (VEGF) therapies and compare the safety, efficacy, and durability of established and emerging therapies for patients with DME.
RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024
This enduring program will examine the burden and unmet needs associated with asthma in the community; review guidelines for diagnosis and step-wise treatment; assess current targeted agents for moderate-to-severe cases of asthma; and present tips on choosing one therapy over another based on patient characteristics, workup, comorbidities, and other considerations. In addition, faculty will discuss case studies that are relevant and useful for everyday practice.
RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024
Using graphical animations, slide-based lecture, and interactive questions, this program will help clinicians identify strategies to reduce uncontrolled asthma cases, review current guidelines for initial and maintenance asthma therapy, improve communication and education to promote better outcomes, and distinguish between targeted agents for the treatment of moderate to severe asthma.
RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024
This activity is designed to meet the educational needs of otolaryngologists, allergists, primary care physicians, nurses, nurse practitioners, pharmacists, and other members of the multidisciplinary team to ensure an up-to-date understanding of the latest data in management of CRSwNP.
Released Date: September 29, 2023
Expiration Date: September 29, 2024
⦁Interpret the unique treatment needs of patients with FH along with their increased risk for ACVD in the short and long term.
⦁Evaluate evidence from clinical trials on therapies for the treatment of patients with FH including long-term CV outcomes
⦁Review the cost and efficacy considerations for FH formulary options such as switching and/or maximizing statins, and implementing newly approved drugs and combinations
RELEASED DATE: August 15, 2023
EXPIRATION DATE: October 11, 2024
This enduring activity will focus on the application and implementation of multicancer early detection (MCED) testing in primary care. The content will review the basics of MCED technology and how it improves cancer detection; describe which patients may be candidates for this type of cancer screening; discuss what test(s) are currently available; and review how these tests can be used in primary care.
RELEASED DATE: October 12, 2023
EXPIRATION DATE: October 12, 2024
This educational activity will examine the burden of prurigo nodularis and the mechanisms of emerging therapies targeting the underlying pathophysiology of the disease. In addition, it will evaluate clinical trial data on the efficacy and safety of current and emerging treatment options and explain the how best to design personalized treatment plans incorporating systemic and topical agents to address symptoms and improve outcomes in patients with prurigo nodularis.
RELEASED DATE: October 16, 2023
EXPIRATION DATE: October 16, 2024
This enduring activity has been designed to increase healthcare professionals’ ability to: evaluate best practices for the assessment and management of patients with Myelofibrosis (MF); contrast available options for specific groups of patients with MF to initiate optimal therapy across lines of treatment; and interpret the latest guideline recommendations for management of MF therapy to minimize the risk of treatment-related adverse events.
RELEASED DATE: October 20, 2023
EXPIRATION DATE: October 20, 2024
This podcast will discuss the importance of understanding the etiopathogenesis of eosinophilic esophagitis (EoE), the role of specific cytokines in this immune-mediated, antigen-driven disease, and the commonly presenting symptomatology as an aid to prompt diagnosis of EoE.
RELEASED DATE: September 28, 2023
EXPIRATION DATE: October 20, 2024
This innovative online activity will evaluate the importance of targeting JAK/STAT signaling in IBD from a pathophysiologic perspective and the role of JAK inhibition in modifying therapeutic outcomes. Learn more about key unmet needs in IBD and the relevance of novel therapy in clinical management, as well as about current perspectives in differential diagnosis, clinical assessment and the appropriate choice of effective therapy in IBD management.
RELEASED DATE: October 23, 2023
EXPIRATION DATE: October 23, 2024
This enduring is aimed to increase participants’ ability to diagnose NTM-LD based on clinical presentation in at-risk patients; apply guidelines and emerging clinical findings to the treatment of individuals with NTM-LD; and use strategies to enhance multidisciplinary communication to improve ongoing monitoring and adverse event management.
RELEASED DATE: October 23, 2023
EXPIRATION DATE: October 23, 2024
This educational activity will help obstetrician-gynecologists and other healthcare professionals better design strategies to facilitate an earlier clinical diagnosis of endometriosis. Additionally, these activities aim to have healthcare professionals assess the benefits associated with the use of medical therapies early in the patient treatment journey and in conjunction with surgery. Ultimately, HCPs should leave this program able to develop treatment plans for the long-term management of endometriosis-associated pain based on results from clinical trials supporting the efficacy and safety of available therapies.
RELEASED DATE: October 13, 2023
EXPIRATION DATE: October 24, 2024
This educational activity will help HCPs identify strategies to manage CRSwNP that are aligned with evidence-based guidelines, discuss the clinical evidence for novel, emerging therapeutic agents for the treatment of CRSwNP, and describe strategies to effectively select treatment based on patient-specific factors and expert guidance.
RELEASED DATE: October 24, 2023
EXPIRATION DATE: October 24, 2024
This enduring educational activity will provide important information on the burden of Paroxysmal Nocturnal Hemoglobinuria (PNH) on patient quality of life, the pathophysiology of PNH, and the latest efficacy and safety data on existing and emerging therapeutic options.
RELEASED DATE: October 19, 2023
EXPIRATION DATE: October 26, 2024
This enduring virtual preceptorship will help clinicians describe symptoms and signs of uncontrolled asthma for prompt diagnosis and appropriate treatment. Additionally, this education will support HCPs as they evaluate strategies for patient-centered communication, education, and shared decision making to potentially reduce the occurrence of low adherence to treatment. HCPs will leave this education with an improved ability to discuss evidence-based treatment selection strategies based on the latest guidelines for symptom control.
RELEASED DATE: October 30, 2023
EXPIRATION DATE: October 30, 2024
This enduring activity has been designed for healthcare professionals to address the needs of patients with lower-risk myelodysplastic syndrome. In particular, the education will help learners diagnose myelodysplastic syndrome earlier and accurately stratify risk; recognize potential resistant to initial therapy in patients with lower-risk myelodysplastic syndrome; and apply best evidence-based practices and clinical data for initial and second-line therapeutic decisions for lower-risk myelodysplastic syndrome.
RELEASED DATE: September 29, 2023
EXPIRATION DATE: October 31, 2024
Following the posting of this activity tirzepatide has received FDA approval for use in adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
This enduring activity provides a comprehensive overview of the chronic disease of obesity and opportunities to improve the quality of care in the primary care setting. It incorporates a variety of interactive tools, including animations and case studies, to create a dynamic learning experience.
RELEASED DATE: August 07, 2023
EXPIRATION DATE: October 31, 2024
This interactive online educational activity focuses on overcoming gaps in management of eosinophilic esophagitis (EoE). Learn more regarding diagnostic delays, prompt recognition of clinical signs and symptoms of EoE, disease etiopathogenesis, and improve awareness of the latest clinical evidence for advanced treatment of EoE through recently approved and emerging targeted biologic therapies.
RELEASED DATE: October 31, 2023
EXPIRATION DATE: October 31, 2024
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD). Providers will learn about the safety, efficacy, and durability of established and emerging nAMD therapies, as well as technological updates that can be used to facilitate patient screening, monitoring, and treatment interval decision-making. This activity uses a unique documentary approach to share a patient story, along with commentary from a retinal disease expert.
RELEASED DATE: October 31, 2023
EXPIRATION DATE: October 31, 2024
This series of five podcasts on multi-cancer early detection technology is geared toward several unique specialty audiences, one each for pulmonologists, OB/GYNs, gastroenterologists, otolaryngologists, and hematology/oncology specialists. The over-arching goals of the program are to review the relevance and need for multi-cancer early detection tests given the gaps in current cancer screening; discuss clinical data and practical use of these tests in specialty practice; and assess ways to discuss MCED testing with patients in a variety of clinical scenarios as these tests continue to become more and more available in the clinic.
RELEASED DATE: October 31, 2023
EXPIRATION DATE: November 09, 2024
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. In this interactive program, we will be discussing results from clinical studies assessing newer treatments for patients with moderate-to-severe plaque psoriasis. Additionally, we will provide tools for integrating these therapies into practice when appropriate, and deliver tips on how to improve shared decision-making and communication to improve outcomes for patients with moderate-to-severe plaque psoriasis.
RELEASED DATE: November 09, 2023
EXPIRATION DATE: November 09, 2024
This enduring program will increase clinicians’ ability to: understand HER2-low levels of expression in patients with gastrointestinal cancer; evaluate clinical trials data for treating patients with advanced HER2 gastrointestinal cancer and apply that to potential treatment options for patients with HER2-low gastrointestinal cancer; and recognize the signs and symptoms of ADC adverse events and apply this knowledge to the management of ADC-related adverse events in patients with HER2-low gastrointestinal cancer.
RELEASED DATE: November 13, 2023
EXPIRATION DATE: November 13, 2024
This enduring case-based activity is designed to assist dermatologists and advanced practice providers in identifying patients with alopecia areata (AA) who may benefit from Janus kinase (JAK) inhibitor therapy. This program will examine factors that contribute to the decision to prescribe JAK inhibitors, review the latest clinical data on their safety and efficacy, and outline strategies to individualize treatment for patients with severe AA using a shared decision-making approach.
RELEASED DATE: November 15, 2023
EXPIRATION DATE: November 15, 2024
This educational activity features a five-episode podcast series in which expert faculty discuss the safety, efficacy, and mechanisms of action of newly approved and emerging ulcerative colitis (UC) therapies, share patient-centered decision-making strategies for UC therapy selection, and emphasize the importance of incorporating bowel urgency and clinical trial outcomes into management strategies for patients with ulcerative colitis.
RELEASED DATE: November 15, 2023
EXPIRATION DATE: November 15, 2024
This educational enduring program is designed to provide gastrointestinal healthcare providers with patient-centered strategies to individualize therapy selection in ulcerative colitis. Using a combination of didactic lecture and animated/video simulation case challenges, this program aims to increase clinician knowledge of the safety, efficacy, and mechanism of action of recently approved and emerging therapies; and improve their ability to incorporate the assessment of bowel urgency into management strategies for patients with ulcerative colitis.
RELEASED DATE: November 15, 2023
EXPIRATION DATE: November 15, 2024
In this brief 30-minute program, noted global expert in lung cancer, Dr. David Planchard, MD, PhD, head of the thoracic cancer group at Gustave Roussy in Villejuif, France, will describe current data informing the management of advanced NSCLC. Based on current clinical evidence, updated guidelines inform the selection of checkpoint inhibition and combinations of checkpoint inhibitors with chemotherapy in the frontline setting. Through appropriate selection of patients for single-agent versus combination regimens in the frontline setting of advanced NSCLC lacking targetable mutations, and awareness of potential adverse events associated with therapy, clinicians will be better equipped to improve therapeutic outcomes for patients.
RELEASED DATE: November 17, 2023
EXPIRATION DATE: November 17, 2024
This case-based enduring TeleECHO educational series will focus on recognizing and managing adverse events associated with antibody-drug conjugate in HER2-targeted therapy for advanced or metastatic breast cancer. Engage with expert discussion to learn more about the benefits of early detection and intervention, and treatment strategies and ways overcome screening barriers in metastatic breast cancer.
RELEASED DATE: November 17, 2023
EXPIRATION DATE: November 17, 2024
This series of podcasts will provide healthcare professionals with valuable information aimed at improving the standard of care for patients with metastatic hormone-sensitive prostate cancer (mHSPC). In this series of succinct, engaging podcasts, experts discuss the latest evidence-based guideline recommendations, multidisciplinary care approaches, and strategies to improve shared decision making and access to equitable care for patients with mHSPC.
RELEASED DATE: November 17, 2023
EXPIRATION DATE: November 17, 2024
The enduring activity with specialty tracks of content has been designed to meet the educational needs of US-based health care providers who treat patients with Growth Hormone Deficiency (GHD), as well as patients and their caregivers. This program will help participants better: assess the tools used to diagnose patients quickly and accurately; evaluate results of approved and emerging therapies for the treatment of pediatric and adult patients with GHD from clinical trials; summarize the long‐term management of strategies on the dosing and monitoring of pediatric and adult patients with GHD; facilitate continuity of care for pediatric patients transitioning into adulthood.
RELEASED DATE: November 20, 2023
EXPIRATION DATE: November 20, 2024
This program is designed to help clinicians explore strategies to identify and improve the quality of life for patients with moderate-to-severe atopic dermatitis (AD); explain the safety and efficacy of systemic treatments for patients with moderate-to-severe AD; and apply the clinical evidence of studies showing benefit of therapeutic agents into patient-specific treatment selection strategies.
RELEASED DATE: November 20, 2023
EXPIRATION DATE: November 20, 2024
This enduring educational activity focuses on the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma. The program aims to help healthcare professionals improve their ability to evaluate which patient populations may benefit from anti-angiogenic therapy as a second-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers, and to select appropriate second- and subsequent-line therapy based on clinical practice guidelines and the latest clinical trial findings.
RELEASED DATE: October 13, 2023
EXPIRATION DATE: November 28, 2024
This enduring activity will help healthcare professionals identify evidence-based strategies to manage Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), understand the clinical evidence for novel, emerging therapies for CRSwNP, and choose the most appropriate treatment based on individual patient characteristics.
RELEASED DATE: November 29, 2023
EXPIRATION DATE: November 29, 2024
This innovative educational symposium is designed to advance interdisciplinary collaboration among clinicians who manage patients with cardio-renal-metabolic comorbidities. Using a combination of didactic lecture and simulation case challenges tailored to a primary audience of primary care physicians and a secondary audience of cardiologists, nephrologists, endocrinologists, hospitalists, physician assistants, nurse practitioners, pharmacists, and certified diabetes educators, this program aims to increase clinician knowledge of the application of SGLT2 inhibitors to the management of heart failure and chronic kidney disease as well as improve their ability to effectively communicate with all members of the multidisciplinary care team to optimize patient care.
RELEASED DATE: November 29, 2023
EXPIRATION DATE: November 29, 2024
This enduring activity has been designed to meet the educational needs of health care providers who diagnose, treat, and/or manage patients with chronic spontaneous urticaria (CSU). We aim to help healthcare practitioners to better understand the etiopathogenesis of CSU, enabling prompt diagnosis and treatment initiation. The program will present clinical trial data on emerging biologics targeting the underlying pathophysiology of CSU, and will identify strategies to individualize patient management to best achieve treatment goals.
RELEASED DATE: November 30, 2023
EXPIRATION DATE: November 30, 2024
This enduring program is designed for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML and will enhance our target healthcare practitioner’s (HCP) ability to: appraise the latest molecular and genetic data in AML and CLL management; justify best practices in management of newly diagnosed relapsed/refractory AML and CLL considering specific patient-related and disease-related factors to inform management; and assess potential adverse events concerning AML and CLL to ensure optimal monitoring and management.
RELEASED DATE: November 30, 2023
EXPIRATION DATE: November 30, 2024
This interactive, case-based enduring meeting is designed to foster learner collaboration and decision-making for various presentations of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Learn and apply the latest updates in treatment, including novel therapeutic formulations as well as considerations on patient related factors and dosing strategies to individualize care in nAMD and DME.
RELEASED DATE: November 30, 2023
EXPIRATION DATE: November 30, 2024
This enduring program will present actionable evidence regarding targeted therapies for spondyloarthritis (SpA) and provide strategies for facilitating shared decision making to enable optimal outcomes for patients with these debilitating conditions. Rheumatology clinicians will gain the knowledge and competence to differentiate between SpA conditions and make a timely diagnosis; apply the latest clinical evidence on targeted therapies such as IL-17 antagonists to treatment decisions; and optimize shared decision making and collaboration across the multidisciplinary care team.
RELEASED DATE: December 07, 2023
EXPIRATION DATE: December 07, 2024
This enduring educational program will help participants understand the role of HER3 biology to better manage patients with advanced non-small cell lung cancer (NSCLC), including EGFR tyrosine kinase inhibition (TKI)-resistant tumors; review HER3-targeted therapeutics available for patients with advanced NSCLC with EGFR-activating mutations; and highlight the value of multidisciplinary management of treatment-related adverse events. This enduring program combines didactic instruction with case-based discussions and animations.
RELEASED DATE: December 08, 2023
EXPIRATION DATE: December 08, 2024
These educational Whiteboard Snapshot online enduring programs focus on the latest updates in novel-targeted and immunotherapeutic approaches of cutaneous malignancies, including identifying targetable mutations and determining eligibility for immunotherapy. Additional considerations regarding pearls for adverse event recognition and management, as well as leveraging shared decision making and the multidisciplinary team are included as part of a comprehensive approach to care in cutaneous malignancies.
RELEASED DATE: December 12, 2023
EXPIRATION DATE: December 12, 2024
This program will inform clinicians of the rationale for use of immunotherapy in cutaneous squamous cell carcinoma (cSCC), including the reasoning behind investigations of its use in the neoadjuvant and adjuvant settings. Through the immersive 3D animations, clinicians will be exposed to current perspectives on the pathophysiology of early cSCC, how immunotherapy before and/or after surgery may improve outcomes, and available data from clinical study of neoadjuvant immunotherapy for cSCC.
RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024
This educational activity offers essential guidance to a diverse range of healthcare professionals, enabling them to effectively integrate SGLT2 inhibitors into treatment strategies for patients with T2DM, CKD, and/or heart failure. Through this program, clinicians will gain insights from in-depth discussions on mechanisms of SGLT2 inhibitors, practice guidelines, FDA indications, clinical trial data, multidisciplinary care approaches, and practical applications, thereby enhancing patient care and outcomes.
RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024
This program will inform clinicians of immunopathological assessment of melanoma especially in relation to patterns of resistance, the advantages of novel combination immunotherapies in the treatment of melanoma, and the evaluation of associated toxicities and their management in patients.
RELEASED DATE: December 15, 2023
EXPIRATION DATE: December 15, 2024
This enduring program will summarize the role of antibody therapeutics; evaluate current clinical trial data on antibody therapeutics and analyze adverse event management best practices for the multidisciplinary oncology care team using antibody therapeutics.
RELEASED DATE: December 20, 2023
EXPIRATION DATE: December 20, 2024
This Virtual Preceptorship invites learners to experience a virtual didactic presentation aimed to help HCPs better understand the roles of the interleukins (IL)-4, IL-5, IL-13, and IL-33 proinflammatory cytokine signaling pathways in the etiopathogenesis of chronic obstructive pulmonary disease (COPD) disease mechanisms; to assess data from studies investigating the clinical profiles of emerging biologic therapies for treating COPD; and formulate multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the COPD care continuum.
RELEASED DATE: December 21, 2023
EXPIRATION DATE: December 21, 2024
This podcast series will focus on improving the ability of healthcare professionals (HCPs) to accurately assess recurrence risk in the patient with either basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC); increasing communication and coordination for the oncology team to optimize the care of high-risk patients with appropriate use of immune checkpoint therapy in NMSC; and ensuring the consistent application of evidence-based oncology recommendations for patients with either BCC or cSCC for clinicians treating NMSC within the Department of Veterans Affairs.
RELEASED DATE: January 02, 2024
EXPIRATION DATE: January 02, 2025
This CME activity seeks to help pharmacists and pharmacy technicians explain the ramifications of respiratory syncytial virus (RSV) and its symptoms in the elderly by reviewing the clinical trials evaluating recently approved and emerging RSV vaccines with various mechanisms of action. This program will also explore those tactics in clinical practice to educate older adults on RSV prevention and mitigate bias in care.
RELEASED DATE: January 04, 2024
EXPIRATION DATE: January 04, 2025
This enduring program will provide clinicians who care for people with gastric and gastroesophageal junction cancers with important updates about current and future management of the diseases. It includes two animations and case study discussions.
RELEASED DATE: January 05, 2024
EXPIRATION DATE: January 05, 2025
In this series of two podcasts, Dr. Alexis Ogdie will discuss the clinical manifestations of spondyloarthritis in order to differentiate it from other pain-related conditions. This includes discussion of the differences between axial spondyloarthritis and peripheral spondyloarthritis. In addition, Dr. Ogdie will discuss treatment strategies, both novel and conventional, and describe the importance of shared decision-making and multidisciplinary collaboration in pursuing the best treatment outcomes.
RELEASED DATE: January 12, 2024
EXPIRATION DATE: January 12, 2025
This enduring is designed to assist veterans’ affairs-associated members of the multi-disciplinary oncology care team in evaluating current developments in the use of novel bispecific antibody therapies in later-line management of Non-Hodgkin’s Lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and current efficacy and safety data associated with adverse event management in NHL.
RELEASED DATE: January 18, 2024
EXPIRATION DATE: January 18, 2025
This Virtual Preceptorship invites learners to explore the mechanisms of bispecific antibodies in the management of relapsed/refractory multiple myeloma. Novel bispecific antibodies simultaneously target CD3 on immune T cells and a target on malignant B cells, such as BCMA. By guiding T cells to malignant myeloma cells, bispecific antibodies enable the precise immune attack of malignant cells. In the process of immune attack, bispecific antibodies may trigger adverse events that require careful monitoring and multidisciplinary management. In this virtual reality program, clinicians will gain perspectives on both mechanisms and safe use of bispecific antibodies in patients with relapsed/refractory multiple myeloma.
RELEASED DATE: January 24, 2024
EXPIRATION DATE: January 24, 2025
Through this virtual preceptorship program, learners will evaluate current and emerging applications of bispecific antibodies in the management of non-Hodgkin lymphoma, as informed by the latest data. With multiple novel bispecific antibodies targeting CD20 on malignant B cells and CD3 on immune effector T cells, there is an increasing need for awareness of the efficacy, safety, and best practices for use of these therapies in relapsed and refractory forms of non-Hodgkin lymphomas. In addition to recognizing clinical data and mechanisms, this program discusses potential adverse events associated with bispecific antibody therapies and best practices for their monitoring and management. This unique program enables clinicians to understand the design, mechanisms, and safety and efficacy data informing the integration of bispecific antibodies in management of non-Hodgkin lymphomas.
RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025
This enduring TeleECHO educational series is designed to assist members of the multi-disciplinary oncology care team in identifying approaches to the use of novel bispecific antibody therapies in later-line management of B-cell non-Hodgkin’s lymphoma (NHL). This program features expert analysis of the latest clinical trial outcomes and potential adverse events associated with bispecific antibody therapy, as well as discussion of best practices for multidisciplinary management of B-cell NHL to improve long-term clinical outcomes.
RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025
This Immersive Simulation experience focuses on strategies to overcome resistance to endocrine therapy in early HR+/HER2- breast cancer. Through the Simulation Center activity, healthcare practitioners will develop a plan to help patients consistently and tolerably use oral anti-cancer medications for HR+/HER2- breast cancer. The program will analyze clinical trial data on CDK4/6 inhibitors in early HR+/HER2- breast cancer to optimize monitoring and managing treatment-associated adverse events. Additionally, healthcare practitioners will develop strategies to support patients in their adherence and persistence with agreed-upon treatment plan for HR+/HER2- early breast cancer.
RELEASED DATE: January 30, 2024
EXPIRATION DATE: January 30, 2025
This interactive program will provide clinicians who care for people with multiple myeloma with important updates about current and future management of the diseases. It includes two animations and case study discussions.
RELEASED DATE: January 30, 2024
EXPIRATION DATE: January 30, 2025
This enduring activity invites learners to explore the mechanisms of disease-modifying agents to manage Sickle Cell Disease. In consideration of the potential for devastating cerebrovascular outcomes of sickle cell disease, this program focuses on evidence-based guidance and the importance of managing the risk of cerebrovascular events in patients to maximize patient outcomes. By visualizing available mechanisms involved in the pathophysiology of sickle cell disease, participants will conceptualize the specific pathways targeted by available therapies, identify risk factors for adverse cerebrovascular outcomes, and bring together all available data to inform the optimal use of disease-modifying therapies for patients with sickle cell disease.
RELEASED DATE: January 31, 2024
EXPIRATION DATE: January 31, 2025
These enduring activities use a unique documentary approach to share the patient experience of diagnosis and treatment of cutaneous malignancies. It highlights their experiences with surgery, radiation, chemotherapy, and immunotherapy with commentary from our faculty expert. The goal is to help learners identify potential immune targets and systemic treatment strategies; optimize multidisciplinary management; and incorporate shared decision making in arriving at individualized care for their patients with cutaneous malignancies.
RELEASED DATE: January 31, 2024
EXPIRATION DATE: January 31, 2025
This podcast will explain the pathophysiology of agitation in Alzheimer’s disease.
RELEASED DATE: February 01, 2024
EXPIRATION DATE: February 01, 2025
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. In this enduring program, we will be discussing results from clinical studies assessing newer treatments for patients with moderate-to-severe plaque psoriasis. Additionally, we will provide tools for integrating these therapies into practice when appropriate, and deliver tips on how to improve shared decision-making and communication to improve outcomes for patients with moderate-to-severe plaque psoriasis.
RELEASED DATE: February 01, 2024
EXPIRATION DATE: February 01, 2025
This enduring HoloVision™ activity is an online program designed to advance community-based oncologists’ ability to: evaluate the biology of TROP2 in breast cancer; examine the rationale for use of TROP2-directed antibody-drug conjugates (ADCs) in breast cancer; recognize adverse effects most commonly associated with ADCs and best practices for their prevention, mitigation, and management; and formulate strategies for integrating TROP2-directed ADCs into breast cancer treatment algorithms.
RELEASED DATE: February 02, 2024
EXPIRATION DATE: February 02, 2025
This CME activity seeks to help pharmacists and pharmacy technicians explain the ramifications of respiratory syncytial virus (RSV) and its symptoms in the elderly by reviewing the clinical trials evaluating recently approved and emerging RSV vaccines with various mechanisms of action. This program will also explore those tactics in clinical practice to educate older adults on RSV prevention and mitigate bias in care.
RELEASED DATE: January 04, 2024
EXPIRATION DATE: Febuary 01, 2025
This educational program focuses on updates in the management of multiple sclerosis and takes a closer look at therapies, quality of life, and safety data. Through an online enduring educational snapshot program, an ECHO Whiteboard TeleECHO series, a smart reach replay of a Whiteboard TeleECHO session, SmartCast™ microlearning podcast series, and point-of-care tools, healthcare practitioners will discuss the burden of multiple sclerosis, including both relapsing and primary progressive forms of the disease, review industry-standard practices for diagnosis and continual assessment of disease course of action, as well as the patient’s functionality, and quality of life. This program will also outline current clinical efficacy and safety data and best practices for evidence-based use of current therapies.
RELEASED DATE: February 02, 2024
EXPIRATION DATE: February 02, 2025
This educational program focuses on strategies to overcome resistance to endocrine therapy in early HR+/HER2- breast cancer. Through this enduring TeleECHO session, healthcare practitioners will develop a plan to help patients consistently and tolerably use oral anti-cancer medications for HR+/HER2- breast cancer. The program will analyze clinical trial data on CDK4/6 inhibitors in early HR+/HER2- breast cancer to optimize monitoring and managing treatment-associated adverse events. Additionally, healthcare practitioners will develop strategies to support patients in their adherence and persistence with agreed-upon treatment plan for HR+/HER2- early breast cancer.
RELEASED DATE: February 08, 2024
EXPIRATION DATE: February 08, 2025
This educational program focuses on strategies to overcome resistance to endocrine therapy in early HR+/HER2- breast cancer. Through this enduring Grand Rounds session, healthcare practitioners will develop a plan to help patients consistently and tolerably use oral anti-cancer medications for HR+/HER2- early breast cancer treatment. The program will review outcomes data from clinical trials on CDK4/6 inhibitors in early HR+/HER2- breast cancer in an effort to improve the monitoring and managing of adverse events. Additionally, healthcare practitioners will develop strategies to help patients adhere to their treatment plan.
RELEASED DATE: February 08, 2024
EXPIRATION DATE: February 08, 2025
Plaque psoriasis is a common, chronic, systemic, immune-mediated inflammatory disease. In this interactive program, we will be discussing results from clinical studies assessing newer treatments for patients with moderate-to-severe plaque psoriasis. Additionally, we will provide tools for integrating these therapies into practice when appropriate, and deliver tips on how to improve shared decision-making and communication to improve outcomes for patients with moderate-to-severe plaque psoriasis.
RELEASED DATE: February 15, 2024
EXPIRATION DATE: February 15, 2025
This Snapshot program is designed to help physicians better summarize the pathophysiologic basis of sickle cell disease (SCD), including the underlying features resulting in heterogeneous clinical presentation; evaluate best practices in transition from pediatric to adult care in patients with SCD; and describe the biologic rationale and mechanism of action of emerging pharmacotherapies for the management of SCD.
RELEASED DATE: February 15, 2024
EXPIRATION DATE: February 15, 2025
This activity will inform clinicians of the latest technological advances for patients with cataract, including practical considerations to improve surgical efficiency. Specifically, the program will discuss improving refractive outcomes with newer pre-operative and intra-operative diagnostic tools including the use of femtosecond-laser assisted surgery and heads-up display visualization systems. These advances, which will also be presented as a whiteboard animation, are changing the landscape for modern cataract surgery.
RELEASED DATE: February 16, 2024
EXPIRATION DATE: February 16, 2025
This program is designed to enhance clinicians’ ability to explain the roles of interleukins (IL)-4/13, IL-33 and other pro-inflammatory cytokine signaling pathways in the etiopathogenesis of chronic obstructive pulmonary disease (COPD) and its disease mechanism, discuss data from clinical studies investigating the clinical profiles of emerging therapies for the treatment of COPD, and describe multidisciplinary, shared decision-making strategies to improve patient-specific communication and education throughout each step of the care continuum of COPD.
RELEASED DATE: February 20, 2024
EXPIRATION DATE: February 20, 2025
This enduring activity will focus on improving the ability of healthcare professionals (HCPs) to accurately assess recurrence risk in the patient with either basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC); increasing communication and coordination for the oncology team to optimize the care of high-risk patients with appropriate use of immune checkpoint therapy in NMSC; and ensuring the consistent application of evidence- based oncology recommendations for patients with either BCC or cSCC for clinicians treating NMSC within the Department of Veterans Affairs.
RELEASED DATE: February 21, 2024
EXPIRATION DATE: February 21, 2025
This program is designed to improve the understanding of the hose involved in the treatment of patients with steroid-resistant chronic graft vs host disease (SR-cGVHD) of the patient perspective of GVHD, its impact on quality of life, and opportunities to individualize treatment.
RELEASED DATE: February 23, 2024
EXPIRATION DATE: February 23, 2025
This educational program focuses on updates in the management of multiple sclerosis and takes a closer look at therapies, quality of life, and safety data. Through an online enduring educational snapshot program, an ECHO Whiteboard TeleECHO series, a smart reach replay of a Whiteboard TeleECHO session, SmartCast™ microlearning podcast series, and point-of-care tools, healthcare practitioners will discuss the burden of multiple sclerosis, including both relapsing and primary progressive forms of the disease, review industry-standard practices for diagnosis and continual assessment of disease course of action, as well as the patient’s functionality, and quality of life. This program will also outline current clinical efficacy and safety data and best practices for evidence-based use of current therapies.
RELEASED DATE: February 23, 2024
EXPIRATION DATE: February 23, 2025
This educational program focuses on next generation sequencing (NGS) panels, which are increasingly used to guide therapy in patients with cancer. The program will address when and how these panels should be used, as well as their impact on the clinical course of cancer. Additionally, the content will look at the variety and types of genomic assays available and how to use them to complement clinical judgement in patients with cancer.
RELEASED DATE: February 26, 2024
EXPIRATION DATE: February 26, 2025
This educational enduring program is designed to provide clinicians who manage patients with Alzheimer’s disease with up-to-date information on agitation in these patients, the impact of agitation on patient and caregiver quality of life, behavioral approaches to managing agitation, and new and investigational medical therapies.
RELEASED DATE: February 28, 2024
EXPIRATION DATE: February 28, 2025
This enduring program will summarize the latest data and guideline recommendations regarding both efficacy and safety of second-line therapeutic options in extensive-stage SCLC, including monitoring and clinical assessment protocols to enable detection and management of potential adverse events.
RELEASED DATE: February 28, 2024
EXPIRATION DATE: February 28, 2025
This podcast will discuss the management of long COVID, including diagnosis, referral pathways, pharmacological and non-pharmacological treatments, and ongoing monitoring.
RELEASED DATE: February 28, 2024
EXPIRATION DATE: February 28, 2025
This innovative educational series will be designed to meet the targeted needs of US-based pulmonologists involved in the diagnosis and management of US Veterans with COPD. Our program aims to enhance clinicians’ ability to review novel COPD diagnostic techniques and apply them into clinical practice for US Veterans; explore the value of the interleukin (IL)-4/13 and IL-33 signaling pathways in novel COPD treatments; and finally, assess current data on new and emerging therapies for the treatment of COPD. The enduring component of this program is designed to further extend its audience reach.
RELEASED DATE: March 01, 2024
EXPIRATION DATE: March 01, 2025
This enduring HoloVision™ activity is an online program designed to advance the abilities of US-based pulmonologists and respiratory therapists and provide the tools to determine an accurate diagnosis of COPD using new diagnostic methods; understand how interleukin (IL)-4/13 and IL-33 signaling pathways affect the pathophysiology of COPD; and review data from clinical studies of the clinical profiles of new and emerging treatments for COPD.
RELEASED DATE: March 01, 2024
EXPIRATION DATE: March 01, 2025
This activity will inform clinicians of the latest technological advances for patients with cataract, including practical considerations to improve surgical efficiency. Specifically, the program will discuss improving refractive outcomes with newer pre-operative and intra-operative diagnostic tools including the use of femtosecond-laser assisted surgery and heads-up display visualization systems. These advances, which will also be presented in an immersive three-dimensional virtual room animation, are changing the landscape for modern cataract surgery.
RELEASED DATE: March 01, 2024
EXPIRATION DATE: March 01, 2025
This Snapshot program is designed to help optometrists and ophthalmologists who care for patients with glaucoma to better understand evidence-based screening recommendations; implement patient-centered communication and education; evaluate the safety, efficacy, and mechanisms of action of new and emerging management approaches, including surgical devices and sustained-release therapies; and integrate 3D visualization systems into patient treatment plans.
RELEASED DATE: February 29, 2024
EXPIRATION DATE: March 01, 2025
This enduring activity will help you evaluate emerging biomarker-driven, tumor-agnostic approaches toward the management of hard-to-treat, advanced solid tumors that express HER2, including cancers of the endometrium, ovary, cervix, bladder, and biliary tract. This activity will review findings from clinical investigations of HER2-directed therapy to treat these tumors, offer practical guidance on multidisciplinary monitoring and management of treatment-related adverse events in patients receiving a HER2-directed therapy; and provide expert perspectives on the role biomarkers play in this strategy. This interactive program combines didactic instruction with case-based discussions and animations.
RELEASED DATE: March 05, 2024
EXPIRATION DATE: March 05, 2025
This program is designed to educate providers that treat patients with CRSwNP to identify symptoms and provide accurate diagnosis; select appropriate treatment regimens based on guideline recommendations; be aware of the latest evidence on novel treatment options; and have a patient-centric lens that can help reduce symptoms and recurrence and improve the quality of life for patients with chronic CRSwNP.
RELEASED DATE: February 29, 2024
EXPIRATION DATE: March 05, 2025
This enduring activity will allow the participant to focus on understanding the strategies for effectively managing moderate-to-severe asthma, to describe the clinical evidence for the use of biologics, to use evidence based strategies to select the optimal therapy for the right patient at the right time, and to understand strategies to provide more effective patient communication to promote better outcomes. Listen to experts discuss the etiopathology of asthma; the different treatment options available; and learn about the various biologics available to manage more advanced and uncontrolled moderate-to-severe asthma, as well as what patient-specific considerations might be taken into account when deciding to use biologics.
RELEASED DATE: March 11, 2024
EXPIRATION DATE: March 11, 2025
This enduring activity focuses on understanding the etiopathologies of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) to optimize the use of medical, surgical, and novel biologic therapies in the management of CRSwNP through assessment of clinical evidence. Patient-specific treatment selection strategies aimed at reducing overall disease burden and optimizing patient quality of life will also be thoroughly addressed. Listen to an expert discuss the immunology behind the disease, the different treatment options commonly employed as initial therapy, the various biologics available to manage difficult-to-treat or recurrent disease, how they work, and what patient-specific considerations might be taken into account when selecting from the various therapies available.
RELEASED DATE: March 11, 2024
EXPIRATION DATE: March 11, 2025
This enduring activity focuses on new developments with biologic therapies when treating moderate-severe AD, shared decision-making between; clinicians, patients, and caregivers, as well as heightened attention to disease burden, including patient quality of life with respect to sleep and social health. A triple-board certified physician in allergy/asthma/immunology, dermatology, and pediatrics reviews the current and emerging treatments for moderate-severe AD as well as best practices for discussing and managing treatments and their side effects with patients over the course of the disease incorporating evidence-based strategies for therapy selection and individualization.
RELEASED DATE: March 11, 2024
EXPIRATION DATE: March 11, 2025
Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.
We are thrilled to announce that we have been recognized as one of the Top 10 Health Education Services Providers by Healthcare Business Review!
This award is both an honor and a testament to our cumulative dedication to providing the best continuing medical education (CME) services to HCPs across the globe. We are proud to be part of this distinguished group and look forward to continuing to have MLG be one of the best CME providers in the country.
Thank you to Healthcare Business Review for this recognition and for shining a light on the importance of accurate and accessible healthcare education.
The Best of America Small Business Website award recognizes the best website launched by a small business since 2021. Technology is a key growth enabler for small businesses. The best in tech track recognizes small businesses as experts in technology and innovation from innovators, app developers, and website creators. Visit our award-winning Ophthalmology and Optometry web portal: vision-relief.com
Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.
Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.